Document:

2007 Stock Option and Incentive Plan and form of agreements thereunder

 Exhibit 10.2 
 

 
 2007 STOCK OPTION AND INCENTIVE PLAN 
  

	SECTION 1.	GENERAL PURPOSE OF THE PLAN; DEFINITIONS 

 The name
of the plan is the Aegerion Pharmaceuticals, Inc. 2007 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors and other key persons (including consultants and
prospective employees) of Aegerion Pharmaceuticals, Inc. (the “Company”) and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary
interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their
efforts on the Company’s behalf and strengthening their desire to remain with the Company. 
 The following terms shall be defined as
set forth below: 
 “Act” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 “Administrator” means either the Board or the compensation Committee of the Board or a similar committee performing the
functions of the compensation committee. 
 “Award” or “Awards,” except where referring to a particular
category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Deferred Stock Awards, Restricted Stock Awards, Unrestricted Stock Awards, Cash-based Awards, Performance Shares and
Dividend Equivalent Rights. 
 “Award Agreement” means a written or electronic agreement setting forth the terms and
provisions applicable to an Award granted under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan. 
 “Board” means the Board of Directors of the Company. 
 “Cash-based Award” means an Award
entitling the recipient to receive a cash-denominated payment. 
 “Code” means the Internal Revenue Code of 1986, as
amended, and any successor Code, and related rules, regulations and interpretations. 
 “Committee” means a committee of the
Board. 
 “Covered Employee” means an employee who is a “Covered Employee” within the meaning of
Section 162(m) of the Code. 

 “Deferred Stock Award” means an Award of phantom stock units to a grantee, subject to
restrictions and conditions as the Administrator may determine at the time of grant. 
 “Dividend Equivalent Right” means an
Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the
grantee. 
 “Effective Date” means the date on which the Plan is approved by stockholders as set forth in Section 20.

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 “Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by
the Administrator; provided, however, that if the Stock is admitted to quotation on a national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination
shall be made by reference to the last date preceding such date for which there are market quotations. 
 “Incentive Stock
Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code. 
 “Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option. 
 “Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5. 
 “Performance-based Award” means any Restricted Stock Award, Deferred Stock Award, Performance Share Award or Cash-based Award granted to a Covered Employee that is intended to qualify as
“performance-based compensation” under Section 162(m) of the Code and the regulations promulgated thereunder. 
 “Performance Shares” means an Award entitling the recipient to acquire shares of Stock upon the attainment of specified performance goals. 
 “Restricted Stock Award” means an Award entitling the recipient to acquire, at such purchase price (which may be zero) as determined by the Administrator, shares of Stock subject to such restrictions
and conditions as the Administrator may determine at the time of grant. 
 “Sale Event” means the consummation of
(i) the dissolution or liquidation of the Company, (ii) the sale of all or substantially all of the assets of the Company and its Subsidiaries on a consolidated basis to an unrelated person or entity, (iii) a merger, reorganization or
consolidation in which the outstanding shares of Stock are converted into or exchanged for 

  

 2 

 
securities of the successor entity and the holders of the Company’s outstanding voting power immediately prior to such transaction do not own at least a
majority of the outstanding voting power of the successor entity immediately upon completion of such transaction (taking into account only ownership interests resulting from pre-transaction interests in the Company), (iv) the sale, in a single
transaction or series of related transactions, of all or a majority of the Stock of the Company to an unrelated person or entity, or (v) any other transaction in which the holders of the Company’s outstanding voting power immediately prior
to such transaction do not own at least a majority of the outstanding voting power of the Company or a successor entity immediately upon completion of the transaction (taking into account only ownership interests resulting from pre-transaction
interests in the Company). 
 “Sale Price” means the value as determined by the Administrator of the consideration payable,
or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event. 
 “Section 409A” means
Section 409A of the Code and the regulations and other guidance promulgated thereunder. 
 “Stock” means the Common
Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to Section 3. 
 “Stock Appreciation
Right” means an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by
the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised. 
 “Subsidiary”
means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly. 
 “Ten Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all
classes of stock of the Company or any parent or subsidiary corporation. 
 “Unrestricted Stock Award” means an Award of
shares of Stock free of any restrictions. 
  

	SECTION 2.	ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS 

 (a) Administrator. The Plan shall be administered by the Administrator. 
 (b) Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including
the power and authority: 
 (i) to select the individuals to whom Awards may from time to time be granted; 
 (ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock
Appreciation Rights, Restricted Stock Awards, Deferred Stock Awards, Unrestricted Stock Awards, Cash-based Awards, Performance 

  

 3 

 
Share Awards and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees; 
 (iii) to determine the number of shares of Stock to be covered by any Award; 
 (iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the
Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the form of written instruments evidencing the Awards; 
 (v) to accelerate at any time the exercisability or vesting of all or any portion of any Award; 
 (vi) subject to the provisions of Section 5(a)(ii), to extend at any time the period in which Stock Options may be exercised; and

 (vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for
its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to
decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. 
 All decisions and
interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. 
 (c) Delegation of
Authority to Grant Options. Subject to applicable law, the Administrator, in its discretion, may delegate to an officer of the Company all or part of the Administrator’s authority and duties with respect to the granting of Stock Options, to
individuals who are (i) not subject to the reporting and other provisions of Section 15 of the Exchange Act and (ii) not Covered Employees. Any such delegation by the Administrator shall include a limitation as to the amount of
Options that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such
action shall not invalidate any prior actions of the Administrator’s delegate or delegates that were consistent with the terms of the Plan. 
 (d) Award Agreement. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award, the provisions
applicable in the event employment or service terminates, and the Company’s authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind an Award. 
 (e) Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act,
omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement
by the Company in respect of any claim, loss, damage or expense (including, 

  

 4 

 
without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s
articles or bylaws or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company. 
 (f) Foreign Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in
which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by
the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable
foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached
to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the
Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards
shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law. 
  

	SECTION 3.	STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION 

 (a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be the sum of (i) 4,000,000 shares and (ii) such number of shares as equals that number of stock options or
awards returned to the Company’s 2006 Stock Option and Grant Plan, as amended and in effect from time to time, after the Effective Date as a result of the expiration, cancellation or termination of such stock options or awards, subject to
adjustment as provided in Section 3(b). For purposes of this limitation, the shares of Stock underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax
withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. Subject to such
overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more than 4,000,000 shares of Stock may be
granted to any one individual grantee during any one calendar year period and no more than 4,000,000 shares may be issued in the form of Incentive Stock Options. The shares available for issuance under the Plan may be authorized but unissued shares
of Stock or shares of Stock reacquired by the Company. 
 (b) Changes in Stock. Subject to Section 3(c) hereof, if, as a result
of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for
a different number or kind of shares or other 

  

 5 

 
securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with
respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of
the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number of
Stock Options or Stock Appreciation Rights that can be granted to any one individual grantee and the maximum number of shares that may be granted under a Performance-based Award, (iii) the number and kind of shares or other securities subject
to any then outstanding Awards under the Plan, (iv) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (v) the price for each share subject to any then outstanding Stock Options and Stock
Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain
exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid
other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such
adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. 
 (c) Mergers and Other
Transactions. Except as the Administrator may otherwise specify with respect to a particular Award in the relevant Award Agreement, in the case of and subject to the consummation of a Sale Event, all Options and Stock Appreciation Rights that
are not exercisable immediately prior to the effective time of the Sale Event shall become fully exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested
and nonforfeitable as of the effective time of the Sale Event, and all other Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the
Administrator’s discretion unless in any case, the parties to the Sale Event agree that Awards will be assumed or continued by the successor entity. Upon the effective time of the Sale Event, the Plan and all outstanding Awards granted
hereunder shall terminate, unless provision is made in connection with the Sale Event in the sole discretion of the parties thereto for the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such
Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any
acceleration hereunder). In the event of such termination, (i) the Company shall have the right, but not the obligation, to make or provide for a cash payment to the grantees holding Options and Stock Appreciation Rights, in exchange for the
cancellation thereof, in an amount equal to the difference between (A) the Sale Price times the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of
the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights, or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as
determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights held by such grantee, including those that will become exercisable upon the 

  

 6 

 
consummation of the Sale Event; provided, however, that the exercise of Options and Stock Appreciation Rights not exercisable prior to the Sale Event shall
be subject to the consummation of the Sale Event. 
 (d) Substitute Awards. The Administrator may grant Awards under the Plan in
substitution for stock and stock based awards held by employees, directors or other key persons of another corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or the acquisition by
the Company or a Subsidiary of property or stock of the employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the Administrator considers appropriate in the circumstances. Any
substitute Awards granted under the Plan shall not count against the share limitation set forth in Section 3(a). 
  

	SECTION 4.	ELIGIBILITY 

 Grantees under the Plan will be such
full or part-time officers and other employees, directors and key persons (including consultants and prospective employees) of the Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion.

  

	SECTION 5.	STOCK OPTIONS 

 (a) Any Stock Option granted under
the Plan shall be in such form as the Administrator may from time to time approve. 
 (b) Stock Options granted under the Plan may be either
Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Code. To
the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option. 
 (c) Stock
Options granted pursuant to this Section 5(a) shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.
If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee’s election, subject to such terms and conditions as the Administrator may establish. 
 (i) Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5(a)
shall be determined by the Administrator at the time of grant but shall not be less than one hundred percent (100%) of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner,
the option price of such Incentive Stock Option shall be not less than one hundred ten percent (110%) of the Fair Market Value on the grant date. 
 (ii) Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an
Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant. 
  

 7 

 (iii) Exercisability; Rights of a Stockholder. Stock Options shall become
exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An
optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. 
 (iv) Method of Exercise. Stock Options may be exercised in whole or in part, by giving written notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price
may be made by one or more of the following methods to the extent provided in the Option Award Agreement: 
 (A) In cash, by
certified or bank check or other instrument acceptable to the Administrator; 
 (B) Through the delivery (or attestation to
the ownership) of shares of Stock that have been purchased by the optionee on the open market or that are beneficially owned by the optionee and are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at
Fair Market Value on the exercise date. To the extent required to avoid variable accounting treatment under FAS 123R or other applicable accounting rules, such surrendered shares shall have been owned by the optionee for at least six months; or

 (C) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to
a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall
comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure. 
 Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a
Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other
requirements contained in the Option Award Agreement or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to
pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of shares attested to. In the event
that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock
Options may be permitted through the use of such an automated system. 
  

 8 

 (v) Annual Limit on Incentive Stock Options. To the extent required for
“incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and
any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall
constitute a Non-Qualified Stock Option. 
  

	SECTION 6.	STOCK APPRECIATION RIGHTS 

 (a) Exercise Price of
Stock Appreciation Rights. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant. 
 Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option
granted pursuant to Section 5 of the Plan. 
 (b) Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights
shall be subject to such terms and conditions as shall be determined from time to time by the Administrator. The maximum term for Stock Appreciation Rights is ten (10) years. 
  

	SECTION 7.	RESTRICTED STOCK AWARDS 

 (a) Nature of
Restricted Stock Awards. The Administrator shall determine the restrictions and conditions applicable to each Restricted Stock Award at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or
achievement of pre-established performance goals and objectives. The grant of a Restricted Stock Award is contingent on the grantee executing the Restricted Stock Award Agreement. The terms and conditions of each such Award Agreement shall be
determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. 
 (b) Rights as a
Stockholder. Upon execution of the Restricted Stock Award Agreement and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Stock, subject to such conditions
contained in the Restricted Stock Award Agreement. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Stock shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that
they are subject to forfeiture until such Restricted Stock are vested as provided in Section 7(d) below, and (ii) certificated Restricted Stock shall remain in the possession of the Company until such Restricted Stock is vested as provided
in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe. 
 (c) Restrictions. Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically
provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in 

  

 9 

 
the Award Agreement or, subject to Section 17 below, in writing after the Award Agreement is issued, if any, if a grantee’s employment (or other
service relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Stock that has not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action
by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price from such grantee or such grantee’s legal representative simultaneously with such termination of employment (or other service
relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of unvested Restricted Stock that are represented by physical
certificates, a grantee shall surrender such certificates to the Company upon request without consideration. 
 (d) Vesting of Restricted
Stock. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Stock and the
Company’s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall
no longer be Restricted Stock and shall be deemed “vested.” Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section 17 below, in writing after the Award Agreement is issued, a
grantee’s rights in any shares of Restricted Stock that have not vested shall automatically terminate upon the grantee’s termination of employment (or other service relationship) with the Company and its Subsidiaries and such shares shall
be subject to the provisions of Section 7(c) above. 
  

	SECTION 8.	DEFERRED STOCK AWARDS 

 (a) Nature of Deferred
Stock Awards. The Administrator shall determine the restrictions and conditions applicable to each Deferred Stock Award at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of
pre-established performance goals and objectives. The grant of a Deferred Stock Award is contingent on the grantee executing the Deferred Stock Award Agreement. The terms and conditions of each such Award Agreement shall be determined by the
Administrator, and such terms and conditions may differ among individual Awards and grantees. At the end of the deferral period, the Deferred Stock Award, to the extent vested, shall be settled in the form of shares of Stock. 
 (b) Election to Receive Deferred Stock Awards in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to
receive a portion of future cash compensation otherwise due to such grantee in the form of a Deferred Stock Award. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator
and in accordance with Section 409A and such other rules and procedures established by the Administrator. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such
limitations and other terms and conditions thereon as the Administrator deems appropriate. Any such future cash compensation that the grantee elects to deter shall be converted to a fixed number of phantom stock units based on the Fair Market Value
of Stock on the date the compensation would otherwise have been paid to the grantee but for the deferral. 
  

 10 

 (c) Rights as a Stockholder. A grantee shall have the rights as a stockholder only as to shares of
Stock acquired by the grantee upon settlement of a Deferred Stock Award; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the phantom stock units underlying his Deferred Stock Award, subject to such
terms and conditions as the Administrator may determine. 
 (d) Termination. Except as may otherwise be provided by the Administrator
either in the Award Agreement or, subject to Section 17 below, in writing after the Award Agreement is issued, a grantee’s right in all Deferred Stock Awards that have not vested shall automatically terminate upon the grantee’s
termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason. 
  

	SECTION 9.	UNRESTRICTED STOCK AWARDS 

 Grant or Sale of
Unrestricted Stock. The Administrator may, in its sole discretion, grant (or sell at par value or such higher purchase price as determined by the Administrator), an Unrestricted Stock Award under the Plan. Unrestricted Stock Awards may be
granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee. 
  

	SECTION 10.	CASH-BASED AWARDS 

 (a) Grant of Cash-based
Awards. The Administrator may, in its sole discretion, grant Cash-based Awards to any grantee in such number or amount and upon such terms, and subject to such conditions, as the Administrator shall determine at the time of grant. The
Administrator shall determine the maximum duration of the Cash-based Award, the amount of cash to which the Cash-based Award pertains, the conditions upon which the Cash-based Award shall become vested or payable, and such other provisions as the
Administrator shall determine. Each Cash-based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-based Award shall be made in accordance with
the terms of the Award and may be made in cash or in shares of Stock, as the Administrator determines. 
  

	SECTION 11.	PERFORMANCE SHARE AWARDS 

 (a) Nature of
Performance Share Awards. The Administrator may, in its sole discretion, grant Performance Share Awards independent of, or in connection with, the granting of any other Award under the Plan. The Administrator shall determine whether and to whom
Performance Share Awards shall be granted, the performance goals, the periods during which performance is to be measured and such other limitations and conditions as the Administrator shall determine. 
 (b) Rights as a Stockholder. A grantee receiving a Performance Share Award shall have the rights of a stockholder only as to shares actually
received by the grantee under the Plan and not with respect to shares subject to the Award but not actually received by the grantee. A grantee shall be entitled to receive shares of Stock under a Performance Share Award only upon satisfaction of all
conditions specified in the Performance Share Award agreement (or in a performance plan adopted by the Administrator). 
  

 11 

 (c) Termination. Except as may otherwise be provided by the Administrator either in the Award
agreement or, subject to Section 17 below, in writing after the Award agreement is issued, a grantee’s rights in all Performance Share Awards shall automatically terminate upon the grantee’s termination of employment (or cessation of
service relationship) with the Company and its Subsidiaries for any reason. 
  

	SECTION 12.	DIVIDEND EQUIVALENT RIGHTS 

 (a) Dividend
Equivalent Rights. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of another Award or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement.
Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at
Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof,
in a single installment or installments. A Dividend Equivalent Right granted as a component of another Award may provide that such Dividend Equivalent Right shall be settled upon exercise, settlement, or payment of, or lapse of restrictions on, such
other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. A Dividend Equivalent Right granted as a component of another Award may also contain terms and conditions
different from such other Award. 
 (b) Interest Equivalents. Any Award under this Plan that is settled in whole or in part in cash on
a deferred basis may provide in the grant for interest equivalents to be credited with respect to such cash payment. Interest equivalents may be compounded and shall be paid upon such terms and conditions as may be specified by the grant.

 (c) Termination. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to
Section 17 below, in writing after the Award Agreement is issued, a grantee’s rights in all Dividend Equivalent Rights or interest equivalents granted as a component of another Award that has not vested shall automatically terminate upon
the grantee’s termination of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason. 
  

	SECTION 13.	TRANSFERABILITY OF AWARDS 

 (a)
Transferability. Except as provided in Section 13(b) below, during a grantee’s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee’s legal representative or guardian in the event of the
grantee’s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution. No Awards shall be subject, in whole or in part, to
attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void. 
  

 12 

 (b) Administrator Action. Notwithstanding Section 13(a), the Administrator, in its
discretion, may provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Awards (other than any Incentive Stock Options) to his or her
immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and
conditions of this Plan and the applicable Award. 
 (c) Family Member. For purposes of Section 13(b), “family member”
shall mean a grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive
relationships, any person sharing the grantee’s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the
grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests. 
 (d) Designation of Beneficiary. Each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or
after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if
the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate. 
  

	SECTION 14.	TAX WITHHOLDING 

 (a) Payment by Grantee.
Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or
make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent
permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company’s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned
on tax withholding obligations being satisfied by the grantee. 
 (b) Payment in Stock. Subject to approval by the Administrator, a
grantee may elect to have the Company’s minimum required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an
aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due. 
  

 13 

	SECTION 15.	ADDITIONAL CONDITIONS APPLICABLE TO NONQUALIFIED DEFERRED COMPENSATION UNDER SECTION 409A. 

 In the event any Stock Option or Stock Appreciation Right under the Plan is materially modified and deemed a new grant at a time when the Fair Market
Value exceeds the exercise price, or any other Award is otherwise determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the following additional conditions shall
apply and shall supersede any contrary provisions of this Plan or the terms of any agreement relating to such 409A Award. 
 (a) Exercise
and Distribution. Except as provided in Section 15(b) hereof, no 409A Award shall be exercisable or distributable earlier than upon one of the following: 
 (i) Specified Time. A specified time or a fixed schedule set forth in the written instrument evidencing the 409A Award. 

(ii) Separation from Service. Separation from service (within the meaning of Section 409A) by the 409A Award grantee;
provided, however, that if the 409A Award grantee is a “key employee” (as defined in Section 416(i) of the Code without regard to paragraph (5) thereof) and any of the Company’s Stock is publicly traded on an established
securities market or otherwise, exercise or distribution under this Section 15(a)(ii) may not be made before the date that is six months after the date of separation from service. 
 (iii) Death. The date of death of the 409A Award grantee. 
 (iv) Disability. The date the 409A Award grantee becomes disabled (within the meaning of Section 15(c)(ii) hereof).

 (v) Unforeseeable Emergency. The occurrence of an unforeseeable emergency (within the meaning of
Section 15(c)(iii) hereof), but only if the net value (after payment of the exercise price) of the number of shares of Stock that become issuable does not exceed the amounts necessary to satisfy such emergency plus amounts necessary to pay
taxes reasonably anticipated as a result of the exercise, after taking into account the extent to which the emergency is or may be relieved through reimbursement or compensation by insurance or otherwise or by liquidation of the grantee’s other
assets (to the extent such liquidation would not itself cause severe financial hardship). 
 (vi) Change in Control
Event. The occurrence of a Change in Control Event (within the meaning of Section 15(c)(i) hereof), including the Company’s discretionary exercise of the right to accelerate vesting of such grant upon a Change in Control Event or to
terminate the Plan or any 409A Award granted hereunder within 12 months of the Change in Control Event. 
 (b) No Acceleration. A 409A
Award may not be accelerated or exercised prior to the time specified in Section 15(a) hereof, except in the case of one of the following events: 
 (i) Domestic Relations Order. The 409A Award may permit the acceleration of the exercise or distribution time or schedule to an individual other than the grantee as may be necessary to comply with the terms of
a domestic relations order (as defined in Section 414(p)(1)(B) of the Code). 
  

 14 

 (ii) Conflicts of Interest. The 409A Award may permit the acceleration of the
exercise or distribution time or schedule as may be necessary to comply with the terms of a certificate of divestiture (as defined in Section 1043(b)(2) of the Code). 
 (iii) Change in Control Event. The Administrator may exercise the discretionary right to accelerate the vesting of such 409A Award
upon a Change in Control Event or to terminate the Plan or any 409A Award granted thereunder within 12 months of the Change in Control Event and cancel the 409A Award for compensation. 
 (c) Definitions. Solely for purposes of this Section 15 and not for other purposes of the Plan, the following terms shall be defined as set
forth below: 
 (i) “Change in Control Event” means the occurrence of a change in the ownership of the Company, a
change in effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company (as defined in Section 1.409A-3(g) of the proposed regulations promulgated under Section 409A by the Department
of the Treasury on September 29, 2005 or any subsequent guidance). 
 (ii) “Disabled” means a grantee who
(i) is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12
months, or (ii) is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement
benefits for a period of not less than three months under an accident and health plan covering employees of the Company or its Subsidiaries. 
 (iii) “Unforeseeable Emergency” means a severe financial hardship to the grantee resulting from an illness or accident of the grantee, the grantee’s spouse, or a dependent (as defined in
Section 152(a) of the Code) of the grantee, loss of the grantee’s property due to casualty, or similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the grantee. 
  

	SECTION 16.	TRANSFER, LEAVE OF ABSENCE, ETC. 

 For purposes of
the Plan, the following events shall not be deemed a termination of employment: 
 (a) a transfer to the employment of the Company from a
Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or 
 (b) an approved leave of absence for military
service or sickness, or for any other purpose approved by the Company, if the employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the
Administrator otherwise so provides in writing. 
  

 15 

	SECTION 17.	AMENDMENTS AND TERMINATION 

 The Board may, at any
time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall adversely affect rights under
any outstanding Award without the holder’s consent. Except as provided in Section 3(b) or 3(c), in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation
Rights or effect repricing through cancellation and re-grants without shareholder approval. To the extent required under the rules of any securities exchange or market system on which the Stock is then listed, to the extent determined by the
Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code or to ensure that compensation earned under Awards qualifies as performance-based compensation
under Section 162(m) of the Code, Plan amendments shall be subject to approval by the Company stockholders entitled to vote at a meeting of stockholders. Nothing in this Section 17 shall limit the Administrator’s authority to take any
action permitted pursuant to Section 3(c). 
  

	SECTION 18.	STATUS OF PLAN 

 With respect to the portion of any
Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise
expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company’s obligations to deliver Stock or make payments with respect to
Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence. 
  

	SECTION 19.	GENERAL PROVISIONS 

 (a) No Distribution. The
Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof. 
 (b) Delivery of Stock Certificates. Stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or
a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all
purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with
the Company, notice of issuance and recorded the issuance in its records (which may include electronic “book entry” records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any
certificates evidencing shares of Stock pursuant to the exercise of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance
and delivery of such certificates is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the 

  

 16 

 
shares of Stock are listed, quoted or traded. All Stock certificates delivered pursuant to the Plan shall be subject to any stop-transfer orders and other
restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place
legends on any Stock certificate to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and
representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or
other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator. 
 (c) Stockholder Rights. Until Stock is deemed delivered in accordance with Section 19(b), no right to vote or receive dividends or any other
rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award. 
 (d) Other Compensation Arrangements; No Employment Rights. Nothing contained in this Plan shall prevent the Board from adopting other or
additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to
continued employment with the Company or any Subsidiary. 
 (e) Trading Policy Restrictions. Option exercises and other Awards under
the Plan shall be subject to the Company’s insider trading policy and procedures, as in effect from time to time. 
 (f) Forfeiture
of Awards under Sarbanes-Oxley Act. If the Company is required to prepare an accounting restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws,
then any grantee who is one of the individuals subject to automatic forfeiture under Section 304 of the Sarbanes-Oxley Act of 2002 shall reimburse the Company for the amount of any Award received by such individual under the Plan during the
12-month period following the first public issuance or filing with the United States Securities and Exchange Commission, as the case may be, of the financial document embodying such financial reporting requirement. 
  

	SECTION 20.	EFFECTIVE DATE OF PLAN 

 This Plan shall become effective upon later of approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or pursuant to written consent or the consumation of the
first fully underwritten, firm commitment public offering of the Company’s Stock pursuant to an effective registration statement under the Act. No grants of Stock Options and other Awards may be made hereunder after the tenth (10th) anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth (10th) anniversary of the date the Plan is approved by the Board. 
  

 17 

	SECTION 21.	GOVERNING LAW 

 This Plan and all Awards and actions
taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles. 
 DATE APPROVED BY BOARD OF DIRECTORS: April 24, 2007 
 DATE APPROVED BY STOCKHOLDERS: May 25, 2007 
  

 18 

 

 
 INCENTIVE STOCK OPTION AGREEMENT 
 UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2007 STOCK OPTION AND INCENTIVE PLAN

 Name of Optionee:_____________________________ 
 No. of Option
Shares:___________________________ 
 Option Exercise Price per Share: $_____________________________________ 
                                       
                  [FMV on Grant Date (110% of FMV if a 10% owner)] 
 Grant Date:____________________ 
 Expiration Date:_____________________________________ 
                                 [up to 10 years (5 if a 10% owner)]

 Pursuant to the Aegerion Pharmaceuticals, Inc. 2007 Stock Option and Incentive Plan, as amended through the date hereof (the
“Plan”), Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number
of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. 
 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth
below, and subject to the discretion of the Administrator (as defined in Section 1 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on
the dates indicated: 
  

			
	 Incremental Number of
Option Shares Exercisable*
	  	 Exercisability Date

		  	
		
		  	
		
		  	
		
		  	
		
		  	

  

	*	Max. of $100,000 per yr. 

 Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the
close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 
 2. Manner of Exercise. 
 (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. 
 Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection. 
 The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon the Company’s receipt from the Optionee of full payment for the Option Shares, as set forth above and any
agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in
compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the
exercise of the Stock Option shall be net of the shares attested to. 
 (b) The shares of Stock purchased upon exercise of
this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such
issuance and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of
a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the
Optionee, and the Optionee’s name shall have been 

  

 2 

 
entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with
respect to such shares of Stock. 
 (c) The minimum number of shares with respect to which this Stock Option may be exercised
at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. 
 (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration
Date hereof. 
 3. Termination of Employment. If the Optionee’s employment by the Company or a Subsidiary (as defined in the
Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. 
 (a) Termination Due to Death. If the Optionee’s employment terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date shall become fully exercisable and may thereafter be
exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. 
 (b) Termination Due to Disability. If the Optionee’s employment terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on
such date shall become fully exercisable and may thereafter be exercised by the Optionee for a period of 12 months from the date of termination or until the Expiration Date, if earlier. The death of the Optionee during the 12-month period provided
in this Section 3(b) shall extend such period for another 12 months from the date of death or until the Expiration Date, if earlier. 
 (c) Termination for Cause. If the Optionee’s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect.
For purposes hereof, “Cause” means any of the following: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, misconduct, neglect of duties, theft, fraud, or breach of
fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach of an employment, consulting or other agreement with the Company; or (v) the conviction of a felony, or any crime involving moral
turpitude, including a plea of guilty or nolo contendre. 
 (d) Other Termination. If the Optionee’s
employment terminates for any reason other than the Optionee’s death, the Optionee’s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to
the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall
terminate immediately and be of no further force or effect. 
 The Administrator’s determination of the reason for termination of the
Optionee’s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees. 
  

 3 

 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall
be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a
different meaning is specified herein. 
 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not
transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the
Optionee’s legal representative or legatee. 
 6. Status of the Stock Option. This Stock Option is intended to qualify as an
“incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult
with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements.
To the extent any portion of this Stock Option does not so qualify as an “incentive stock option,” such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift,
transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so
notify the Company within 30 days after such disposition. 
 7. Tax Withholding. The Optionee shall, not later than the date as of
which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be
withheld on account of such taxable event. The Optionee may elect to have the minimum required tax withholding obligation satisfied, in whole or in part, by (i) authorizing the Company to withhold from shares of Stock to be issued, or
(ii) transferring to the Company, a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 
 8. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this
Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time. 
  

 4 

 9. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place
of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
					
	Dated:	 	 	 		 		 	 
		 		 		 		 	Optionee’s Signature
					
		 		 		 		 	Optionee’s name and address:
					
		 		 		 		 	 
					
		 		 		 		 	 
					
		 		 		 		 	 

  

 5 

 

 
 NON-QUALIFIED STOCK OPTION AGREEMENT 
 FOR COMPANY EMPLOYEES 
 UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2007 STOCK OPTION AND INCENTIVE PLAN 
 Name of
Optionee:________________________________ 
 No. of Option Shares:_____________________________ 
 Option Exercise Price per Share: $____________________ 
                                       
                  [FMV on Grant Date] 
 Grant
Date:______________________________ 
 Expiration Date:_________________________________ 
 Pursuant to the Aegerion Pharmaceuticals, Inc. 2007 Stock Option and Incentive Plan, as amended through the date hereof (the “Plan”), Aegerion
Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock,
par value $0.001 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an
“incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended. 
 1. Exercisability
Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 1 of the Plan) to accelerate
the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated: 
  

			
	 Incremental Number of
Option Shares Exercisable
	  	 Exercisability Date

		  	
		
		  	
		
		  	
		
		  	
		
		  	

 Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the
close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 
 2. Manner of Exercise. 
 (a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be
purchased. 
 Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by
certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially
owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly
executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to
pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment
procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection. 
 The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon the Company’s receipt from the Optionee of full payment for the Option Shares, as set forth above and any
agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in
compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the
exercise of the Stock Option shall be net of the Shares attested to. 
 (b) The shares of Stock purchased upon exercise of
this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such
issuance and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of
a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the
Optionee, and the Optionee’s name shall have been 

  

 2 

 
entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with
respect to such shares of Stock. 
 (c) The minimum number of shares with respect to which this Stock Option may be exercised
at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. 
 (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration
Date hereof. 
 3. Termination of Employment. If the Optionee’s employment by the Company or a Subsidiary (as defined in the
Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. 
 (a) Termination Due to Death. If the Optionee’s employment terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date shall become fully exercisable and may thereafter be
exercised by the Optionee’s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. 
 (b) Termination Due to Disability. If the Optionee’s employment terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on
such date shall become fully exercisable and may thereafter be exercised by the Optionee for a period of 12 months from the date of termination or until the Expiration Date, if earlier. The death of the Optionee during the 12-month period provided
in this Section 3(b) shall extend such period for another 12 months from the date of death or until the Expiration Date, if earlier. 
 (c) Termination for Cause. If the Optionee’s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect.
For purposes hereof, “Cause” means any of the following: (i) dishonesty, embezzlement, misappropriation of assets or property of the Company; (ii) gross negligence, misconduct, neglect of duties, theft, fraud, or breach of
fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach of an employment, consulting or other agreement with the Company; or (v) the conviction of a felony, or any crime involving moral
turpitude, including a plea of guilty or nolo contendre. 
 (d) Other Termination. If the Optionee’s
employment terminates for any reason other than the Optionee’s death, the Optionee’s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to
the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall
terminate immediately and be of no further force or effect. 
 The Administrator’s determination of the reason for termination of the
Optionee’s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees. 
  

 3 

 4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall
be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a
different meaning is specified herein. 
 5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not
transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the
Optionee’s legal representative or legatee. 
 6. Tax Withholding. The Optionee shall, not later than the date as of which the
exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on
account of such taxable event. The Optionee may elect to have the minimum required tax withholding obligation satisfied, in whole or in part, by (i) authorizing the Company to withhold from shares of Stock to be issued, or
(ii) transferring to the Company, a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due. 
 7. No Obligation to Continue Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this
Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time. 
  

 4 

 8. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place
of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
					
	Dated:	 	 	 		 		 	 
		 		 		 		 	Optionee’s Signature
					
		 		 		 		 	Optionee’s name and address:
					
		 		 		 		 	 
					
		 		 		 		 	 
					
		 		 		 		 	 

  

 5 

 

 
 NON-QUALIFIED STOCK OPTION AGREEMENT 
 FOR NON-EMPLOYEE DIRECTORS 
 UNDER THE AEGERION PHARMACEUTICALS, INC. 

2007 STOCK OPTION AND INCENTIVE PLAN 
 Name of Optionee:
__________________________ 
 No. of Option Shares: ____________ 
 Option Exercise Price per Share: $____________________ 
                                       
                      [FMV on Grant Date] 
 Grant Date: __________________________________ 
 Expiration Date: ________________________ 
                                 [No more than 10 years] 
 Pursuant to the Aegerion Pharmaceuticals, Inc. 2007 Stock Option and Incentive Plan, as amended through the date hereof (the “Plan”), Aegerion
Pharmaceuticals, Inc. (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration
Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions
set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended. 
 1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth
below, and subject to the discretion of the Administrator (as defined in Section 1 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on
the dates indicated: 
  

			
	 Incremental Number of
 Option Shares Exercisable
	 	 Exercisability Date

 In the event of the termination of the Optionee’s service as a director of the Company
because of death, disability or retirement, or in the event of a Sale Event (as defined in Section 1 

 
of the Plan), this Stock Option shall become immediately exercisable in full, whether or not exercisable at such time. Once exercisable, this Stock Option
shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan. 
 2. Manner of Exercise. 
 (a) The Optionee may exercise this Stock Option only in the following manner:
from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This
notice shall specify the number of Option Shares to be purchased. 
 Payment of the purchase price for the Option Shares may be made by one
or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the
Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the
Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price,
provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator
shall prescribe as a condition of such payment procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection. 
 The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon the Company’s
receipt from the Optionee of full payment for the Option Shares, as set forth above and any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of
Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the
attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to. 
 (b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator
with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee.
The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this 

  

 2 

 
Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and
the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock. 
 (c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of
shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time. 
 (d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof. 
 3. Termination as Director. If the Optionee ceases to be a Director of the Company, the period within which to exercise the Stock Option may be
subject to earlier termination as set forth below. 
 (a) Termination for Cause. If the Optionee’s service as a Director is
terminated for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, “Cause” means any of the following: (i) dishonesty, embezzlement,
misappropriation of assets or property of the Company; (ii) gross negligence, misconduct, neglect of duties, theft, fraud, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach of
an agreement with the Company; or (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or nolo contendre. 
 (b) Termination by Reason of Death. If the Optionee ceases to be a Director by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date may be exercised by his or her legal
representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. 
 (c) Other
Termination. If the Optionee ceases to be a Director for any reason other than the Optionee’s death, and other than as a result of termination by the Company for Cause, any portion of this Stock Option outstanding on such date may be
exercised for a period of 12 months from the date of termination or until the Expiration Date, if earlier. 
 4. Incorporation of
Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.
Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 
 5.
Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is
exercisable, during the Optionee’s lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee. 
 6. No Obligation to Continue as a Director. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Director. 
  

 3 

 7. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place
of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 
 8. Amendment. Pursuant to Section 18 of the Plan, the Administrator may at any time amend or cancel any outstanding portion of this Stock
Option, but no such action may be taken that adversely affects the Optionee’s rights under this Agreement without the Optionee’s consent. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 
		 	 Name:
 Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
		 		 	
					
	Dated:	 	 	 		 		 	 
		 		 		 		 	Optionee’s Signature
					
		 		 		 		 	Optionee’s name and address:
					
		 		 		 		 	 
					
		 		 		 		 	 
					
		 		 		 		 	 

  

 4 

 

 
 RESTRICTED STOCK AWARD AGREEMENT 
 UNDER THE AEGERION PHARMACEUTICALS, INC. 
 2007 STOCK OPTION AND INCENTIVE PLAN

 Name of Grantee:_____________________ 
 No. of
Shares:________________________ 
 Grant Date:____________________________ 
 Final Acceptance Date:_________________________ 
 Pursuant to the Aegerion Pharmaceuticals, Inc. 2007 Stock
Option and Incentive Plan (the “Plan”) as amended through the date hereof, Aegerion Pharmaceuticals, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance
of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan.

 1. Acceptance of Award. The Grantee shall have no rights with respect to this Award unless he or she shall have accepted this Award
prior to the close of business on the Final Acceptance Date specified above by (i) signing and delivering to the Company a copy of this Award Agreement, and (ii) delivering to the Company a stock power endorsed in blank. Upon acceptance of
this Award by the Grantee, the shares of Restricted Stock so accepted shall be issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the
Company. Thereupon, the Grantee shall have all the rights of a shareholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. 
 2. Restrictions and Conditions. 
 (a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to
restrictions as set forth herein and in the Plan. 
 (b) Shares of Restricted Stock granted herein may not be sold, assigned,
transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting. 
 (c) If the Grantee’s
employment with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and
automatically be forfeited and returned to the Company. 

 3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this
Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and
conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date. 
  

			
	 Number of
 Shares Vested
	  	 Vesting Date

		  	
		
		  	
		
		  	
		
		  	
		
		  	

 Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and
conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3. 
 4. Dividends. Dividends on Shares of Restricted Stock shall be paid currently to the Grantee. 
 5.
Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of
the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 
 6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. 
 7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income
tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Grantee may elect to have the required
minimum tax withholding obligation satisfied, in whole or in part, by (i) authorizing the Company to withhold from shares of Stock to be issued, or (ii) transferring to the Company, a number of shares of Stock with an aggregate Fair Market
Value that would satisfy the withholding amount due. 
 8. Election Under Section 83(b). The Grantee and the Company hereby agree
that the Grantee may, within 30 days following the acceptance of this Award as provided in 

  

 2 

 
Paragraph 1 hereof, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event
the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. 
 9. No Obligation to Continue
Employment. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the
Company or any Subsidiary to terminate the employment of the Grantee at any time. 
 10. Notices. Notices hereunder shall be mailed or
delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in
writing. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 
		 	Name:
		 	Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the
undersigned. 
  

									
					
	Dated:	 	 	 		 		 	 
		 		 		 		 	Grantee’s Signature
					
		 		 		 		 	Grantee’s name and address:
					
		 		 		 		 	 
					
		 		 		 		 	 
					
		 		 		 		 	 
					
		 		 		 		 	 

  

 3Amended and Restated Investor Rights Agreement, dated November 9, 2007

 Exhibit 10.3 
  
 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 
 This AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT is made as of November 9, 2007 (“Investor Rights Agreement”), by and among Aegerion Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), and the Investors listed on Schedule I attached hereto (the “Investors”). 
 WHEREAS,
the Company and certain of the Investors (the “Prior Investors”) previously entered into an Investor Rights Agreement, dated December 15, 2005 (the “Prior Agreement”), in connection with the purchase of shares
of Series A Preferred Stock of the Company, par value $0.001 per share (“Series A Preferred”); 
 WHEREAS, the Prior
Investors and the Company desire to induce certain of the Investors to purchase shares of Series B Preferred Stock of the Company, par value $0.001 per share, (“Series B Preferred” and together with the Series A Preferred, the
“Preferred Stock”) pursuant to the Series B Preferred Stock Purchase Agreement dated as of the date hereof by and among the Company and certain of the Investors (the “Purchase Agreement”) by amending and restating
the Prior Agreement to provide the Investors with the rights and privileges as set forth herein; and 
 WHEREAS, (i) Section 6.3 of
the Prior Agreement provides that it may be amended with the consent of the Company and the holders of the Required Series A Majority (defined below) and (ii) the undersigned holders represent a Required Series A Majority. 
 NOW, THEREFORE, the Company and the Investors, including the Prior Investors, each hereby agree to amend and restate the Prior Agreement in its entirety
as set forth herein, and the parties hereto further agree as follows: 
 1. GENERAL PROVISIONS 
 1.1 Shares Subject to this Investor Rights Agreement. The Investors expressly agree that the terms and restrictions of this Investor Rights
Agreement shall apply to all shares of capital stock which any of them now owns or hereafter acquires by any means, including, without limitation, by purchase, assignment or operation of law, or as a result of any stock dividend, stock split,
reorganization, reclassification, whether voluntary or involuntary, or other similar transaction, and to any shares of capital stock of any successor in interest of the Company, whether by sale, merger, consolidation or other similar transaction, or
by purchase, assignment or operation of law (the “Shares”). 
 1.2 No Partnership Relationship. Notwithstanding, but
not in limitation of, any other provision of this Investor Rights Agreement, the parties understand and agree that the creation, management and operation of the Company shall not create or imply a general partnership between or among the Investors
and shall not make any Investor the agent or partner of any other Investor for any purpose. 
 1.3 Certain Definitions. As used in
this Investor Rights Agreement, the following terms shall have the following respective meanings: 
 . 

 “Advent International Entity” shall mean any of the following: Advent Healthcare and
Life Sciences III Limited Partnership, Advent Healthcare and Life Sciences III-A Limited Partnership, Advent Partners HLS III Limited Partnership. 
 “Affiliate” of any Person (as defined below) means, with respect to any person or entity, any other person or entity which controls, or is controlled by, or is under common control with the subject referenced and, for the
purposes hereof, the term “control” (including the terms “controlling”, “controlled by” and “under common control with”) shall mean the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of a person or entity, whether through the ownership of voting securities or by contract or otherwise; provided that (A) in the case of any Advent International Entity, “Affiliate” shall
include any other Advent International Entity, (B) in the case of any Index Ventures Entity, “Affiliate” shall include any other Index Ventures Entity, (C) in the case of any Alta Partners Entity, “Affiliate” shall
include any other Alta Partners Entity and (D) in the case of any MVM Entity, “Affiliate” shall include any other MVM Entity. 
 “Alta Partners Entity” shall mean any of the following: Alta BioPharma Partners III, L.P., Alta BioPharma Partners III GmbH & Co. Beteiligungs KG, Alta Embarcadero BioPharma Partners III, LLC. 
 “Amended and Restated Certificate of Incorporation” shall mean the Amended and Restated Certificate of Incorporation of the Company as
filed with the Secretary of State of the State of Delaware on the date hereof, as amended from time to time thereafter in accordance with its terms, the By-laws of the Company, and the laws of the State of Delaware. 
 “Commission” shall mean the U.S. Securities and Exchange Commission and any successor agency of the Federal government administering
the Securities Act and the Exchange Act. 
 “Common Stock” shall mean (i) the common stock, $.001 par value per share,
of the Company, (ii) any other capital stock of the Company, however designated, authorized on or after the date hereof, which shall neither be limited to a fixed sum or percentage of par value in respect of the rights of the holders thereof to
participate in dividends nor entitled to a preference in the distribution of assets upon the voluntary or involuntary liquidation, dissolution or winding up of the Company; and (iii) any other securities into which or for which any of the
securities described in (i) or (ii) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, consolidation, sale of assets or other similar transaction. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and any similar or successor Federal statute, and the rules
and regulations of the Commission promulgated thereunder, all as the same shall be in effect from time to time. 
 “Federal” shall mean with respect to any executive, legislative or judicial branch of government or other agency or organ of government, a branch or other agency or organ of the government of the United States. 

“Index Ventures Entity” shall mean any of the following: Index Ventures III (Jersey) L.P., Index Ventures III (Delaware) L.P., Index
Ventures III Parallel Entrepreneur Fund 

  

 2 

 
(Jersey) L.P. and Yucca Partners LP Jersey Branch as Administrator of The Index Co-Investment Scheme. 
 “MVM Entity” shall mean any of the following: MVM International Life Sciences Fund No. 1 L.P. and MVM Executive Limited.

 “Person” shall mean an individual or group of individuals, a corporation, an association, a partnership, a limited or
general limited liability company, an estate, a trust, and any other entity or organization, governmental or otherwise. 
 “Qualified Public Offering” shall mean a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, in connection with which all of the
Company’s shares of Preferred Stock convert to Common Stock. 
 The terms “register,” “registered”
and “registration” shall mean a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the
effectiveness of such registration statement, or, as the context may require, under the Exchange Act or applicable state securities laws. 
 “Registrable Securities” shall mean (i) shares of Preferred Stock; (ii) shares of Common Stock or other securities issued or issuable pursuant to the conversion of the Preferred Stock; (iii) any shares of
Common Stock directly held by the Investors that are “restricted securities” within the meaning of the Securities Act; and (iv) any shares of Common Stock or other securities issued or issuable with respect to the Preferred Stock by
reason of any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, sale of assets or similar event, excluding in any event securities which have been (a) registered under the Securities Act pursuant to an
effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them or (b) publicly sold pursuant to Rule 144 under the Securities Act. Wherever reference is made in this Investor Rights
Agreement to a request or consent of holders of a certain percentage of Registrable Securities, the determination of such percentage shall be calculated on the basis of shares of Common Stock issued or issuable upon conversion of the Preferred Stock
even if such exercise has not been effected. 
 “Registration Expenses” shall mean the expenses so described in
Section 4.5. 
 “Required Series A/B Majority” shall mean the holders of at least two-thirds of the Series A
Preferred and Series B Preferred, voting together as a class. 
 “Securities Act” shall mean the Securities Act of 1933, as
amended, and any similar or successor Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect from time to time. 
 “Selling Expenses” shall mean the expenses so described in Section 4.5. 
 “Subsidiary” or “Subsidiaries” shall mean any corporation, partnership, trust or other entity of which the Company and/or any of its other Subsidiaries directly or indirectly 

  

 3 

 
owns at the time a majority of the outstanding shares of any class of equity security of such corporation, partnership, trust or other entity. 
 2. PRE-EMPTIVE RIGHTS 
 2.1 Right
of First Offer. Except with respect to “Exempt Issuances” as defined in Section 2.3, in the event that the Company proposes to issue (the “New Issuance”) any (i) shares of Common Stock,
(ii) warrants, options or other rights to purchase Common Stock (collectively, “Rights”), or (iii) any debentures or other securities convertible into or exchangeable for shares of Common Stock (collectively,
“Convertible Securities”), the Company will first offer to sell such securities to the Investors (the “Offer”) and deliver a notice to the Investors (the “Offer Notice”) of such Offer, stating the
price and other terms and conditions thereof (including any definitive documents relating thereto), which Offer by its terms shall remain open and irrevocable for a period of thirty (30) days from the date it is delivered by the Company to the
Investors. 
 2.2 Right to Purchase Shares, Rights or Convertible Securities. 
 (a) The holders of Preferred Stock (the “Preferred Holders”) shall have the right to purchase up to such number of shares of Common
Stock, Rights or Convertible Securities, as applicable, of the New Issuance at the price and on the terms stated in the Offer Notice, such price to be paid in full in cash or by check at the time of issuance of such securities to the Preferred
Holders so that, after giving effect to the New Issuance, each holder of Preferred Stock who exercises such right will continue to maintain its same proportionate ownership of Common Stock as of the date immediately preceding the Offer, treating
each Preferred Holder for the purpose of such computation as the holder of (i) the number of shares of Common Stock which would be issuable to it upon conversion, exercise and exchange of all Rights and Convertible Securities held by it and
(ii) the number of shares of Common Stock directly held by it, in each case on the date immediately preceding the Offer and assuming the like conversion, exercise and exchange of all such securities held by other persons (“Equity
Percentage”). The rights set forth in this Section 2 shall be exercised by the Preferred Holders, if at all, by written notice (the “Acceptance Notice”) to the Company delivered not later than thirty
(30) days after the receipt by the Preferred Holders of the Offer Notice in accordance with the terms and conditions stated therein, and such right shall expire at the end of the twentieth day after the day of the receipt by the Preferred
Holders of the Offer Notice. 
 (b) Each Preferred Holder shall have a right of oversubscription such that if any other Preferred Holder
fails to exercise its right to maintain its Equity Percentage, the other Preferred Holder(s), who do exercise such right, shall, among them, have the right to purchase up to the balance of such securities in the Offer not so purchased. The Investors
may exercise such right of oversubscription by electing to purchase more than their Equity Percentage of the Offer by so indicating in their Acceptance Notice. If, as a result thereof, such oversubscriptions exceed the total number of the securities
in the Offer available in respect to such oversubscription privilege, the oversubscribing Preferred Holders shall be cut back with respect to oversubscriptions on a pro rata basis in accordance with their Equity Percentage or as they may otherwise
agree among themselves. 
  

 4 

 (c) In the event that Acceptance Notices are not given by the Investors in respect of all of the New
Issuance, the Company shall have 120 days from the expiration of the foregoing thirty (30) day period to sell all or any part of such New Issuance to which the Acceptance Notices have not been given by the Investors to any other Person or
Persons, but only upon terms and conditions in all material respects, including, without limitation, share price and dividend rates, which are no more favorable to such other person or persons and no less favorable to the Company than those set
forth in the Offer. A failure by any Investor to exercise its pre-emptive rights under this Section 2 on any occasion shall not act as a waiver of any such rights in respect of future New Issuances. 
 2.3 Exempt Issuances. The term “Exempt Issuances” referred to in Section 2.1 which will not give the Preferred
Holders the rights described in Section 2.2 are (a) issuances of Excluded Securities as such term is defined in Section B(2)(d)(i)(E) of the Amended and Restated Certificate of Incorporation, as such definition may be amended from
time to time, and (b) any sale prior to June 30, 2008, of Series B Preferred to one or more institutional investors, in one transaction or a series of related transactions, made solely for the purposes of capital raising and not in
connection with any strategic license, partnering or similar collaborative or strategic transaction, and in which the gross proceeds to the Company are at least $12.0 million. 
 2.4 Assignment. The rights of the Investors under this Section 2 may be assigned to an Affiliate of an Investor provided such
transferee agrees in writing to be bound to the terms, agreements and restrictions contained in this Investor Rights Agreement. 
 2.5
Termination. The respective rights and obligations of the parties under this Section 2 shall terminate upon the closing of the Company’s Qualified Public Offering. 
 3. TRANSFER OF REGISTRABLE SECURITIES 
 3.1 Restrictive Legend. Each certificate representing Registrable Securities shall, except as otherwise provided in this Section 3.1 or in Section 3.2, be stamped or otherwise imprinted with a legend
substantially in the following form (in addition to any legend required under applicable state securities laws): 
 “The securities
represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws. These securities have been acquired for investment and not with a view to
distribution or resale. Such securities may not be offered for sale, sold, delivered after sale, transferred, pledged or hypothecated in the absence of an effective registration statement covering such securities under the Securities Act and any
other applicable securities laws, unless the holder shall have obtained an opinion of counsel reasonably satisfactory to the corporation that such registration is not required.” 
 Upon the request of a holder of such a certificate, the Company shall remove the foregoing legend from the certificate or issue to such holder a new
certificate therefor free of any 

  

 5 

 
transfer legend, if there is an effective registration statement covering the securities represented by such certificate or, with such request, the Company
shall have received either the opinion referred to in Section 3.2(a)(i) or the “no-action” letter referred to in Section 3.2(a)(ii). 
 3.2 Notice of Proposed Transfer. 
 (a) Prior to any proposed sale, pledge, hypothecation or other
transfer of any Registrable Securities (other than under the circumstances described in Section 4.1, 4.2 or 4.3), the holder thereof shall give written notice to the Company of its intention to effect such sale, pledge,
hypothecation or other transfer. Each such notice shall describe the manner of the proposed sale, pledge, hypothecation or other transfer and, if requested by the Company shall be accompanied by either (i) an opinion of counsel reasonably
satisfactory to the Company to the effect that the proposed sale, pledge, hypothecation or other transfer may be effected without registration under the Securities Act or (ii) a “no action” letter from the Commission to the effect
that the distribution of such securities without registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the holder of such stock shall be entitled to transfer such stock
in accordance with the terms of its notice; provided, however, that no such opinion of counsel or “no action” letter shall be required (i) for a distribution to one or more partners or members of the transferor (in the
case of a transferor that is a partnership or limited liability company) in each case in respect of the beneficial interest of such partner or member; (ii) for any transfer by a Preferred Holder to any Affiliate of such Preferred Holder; or
(iii) for transfers made in accordance with the provisions of Rule 144 (or any rule permitting public sale without registration under the Securities Act) including Rule 144(k). Each certificate for Registrable Securities transferred as above
provided shall bear the appropriate restrictive legend set forth in Section 3.1, except that such certificate shall not bear such legend if (i) such transfer is in accordance with the provisions of Rule 144 (or any other rule
permitting public sale without registration under the Securities Act) or (ii) the opinion of counsel or “no-action” letter referred to above is to the further effect that the transferee and any subsequent transferee (other than an
Affiliate of the Company) would be entitled to transfer such securities in a public sale without registration under the Securities Act or that such legend is not required to establish compliance with any provisions of the Securities Act.
Notwithstanding any other provision hereof, the restrictions provided for in this Section 3.2 shall not apply to securities which are not required to bear the legend prescribed by Section 3.1 in accordance with the provisions
of that Section. 
 (b) No such opinion of counsel or “no action” letter from the Commission, as set forth in
Section 3.2(a) above, shall be required in the event of a sale, pledge, hypothecation or other transfer of any Registrable Securities to (i) any Affiliate of an Investor, including, without limitation, any venture capital limited
partnership now existing or hereafter formed which controls, is controlled by or is under common control with such Investor; and (ii) any successors or assigns of any of the foregoing persons, provided that the transferee agrees in writing to
be subject to this Investor Rights Agreement to the same extent as if such transferee were originally a signatory. 
  

 6 

 4. REGISTRATION 
 4.1 Required Registration. 
 (a) At any time
after the earlier of (i) expiration of the six (6) month period following the closing of the Company’s Qualified Public Offering and (ii) the first (1st) anniversary of the date hereof, one or more of the holders of Registrable Securities constituting a majority of the total shares of Registrable Securities then outstanding may request that the Company register
for sale under the Securities Act up to all of the shares of Registrable Securities held by such holders in the manner specified in such notice. 
 (b) Following receipt of any notice under this Section 4.1(a), the Company shall immediately notify all holders of Registrable Securities from whom notice has not been received and such holders shall then
be entitled within thirty (30) days after receipt of such notice from the Company to request the Company to include in the requested registration all or any portion of their shares of Registrable Securities. The Company shall use its best
efforts to register under the Securities Act for public sale in accordance with the method of disposition specified in the notice from requesting holders described in paragraph (a) above, within one hundred eighty (180) days of its receipt
of such notice, the number of shares of Registrable Securities specified in such notice. The Company shall be obligated to register the Registrable Securities pursuant to this Section 4.1 on one (1) occasion only. Notwithstanding
anything to the contrary contained herein, no request may be made under this Section 4.1 after the effective date of a registration statement filed by the Company covering a firm commitment underwritten public offering and prior to the
later to occur of the completion of the period of distribution for such offering or ninety (90) days after the effective date of such registration statement. 
 (c) If the holders requesting such registration intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made
pursuant to this Section 4.1 and the Company shall include such information in the written notice referred to in paragraph (b) above. The right of any holder to registration pursuant to this Section 4.1 shall be
conditioned upon such holder’s agreeing to participate in such underwriting and to permit inclusion of such holder’s Registrable Securities in the underwriting. The Company’s Board of Directors (the “Board”) shall
designate the managing underwriter of such offering. A holder may elect to include in such underwriting all or a part of the Registrable Securities it holds. 
 (d) A registration statement filed pursuant to this Section 4.1 may, subject to the following provisions, include (i) shares of Common Stock for sale by the Company for its own account and
(ii) shares of Common Stock held by officers or directors of the Company, in each case for sale in accordance with the method of disposition specified by the requesting holders. If such registration shall be underwritten, the Company and such
officers and directors proposing to distribute their shares through such underwriting shall enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting on terms no
less favorable to such officers or directors than the terms afforded the holders of Registrable Securities. If and to the extent that 

  

 7 

 
the managing underwriter determines that marketing factors require a limitation on the number of shares to be included in such registration, such exclusion,
to the extent required by the managing underwriter, shall be applied in the following order: first, to the shares held by the directors and officers and second, to the shares of Common Stock of the Company to be included for its own account. If the
managing underwriter determines that marketing factors require a further limitation of the number of Registrable Securities to be registered under this Section 4.1, then Registrable Securities shall be excluded in such manner that the
securities to be sold shall be allocated among the selling holders pro rata based on their ownership of Registrable Securities. In any event all securities to be sold other than Registrable Securities will be excluded prior to any exclusion of
Registrable Securities. If any holder of Registrable Securities, officer or director who has requested inclusion in such registration as provided above, disapproves of the terms of the underwriting, such holder of securities may elect to withdraw
therefrom by written notice to the Company and the managing underwriter. The securities so withdrawn shall also be withdrawn from registration. Except for registration statements on Form S-4, S-8 or any comparable form or successor thereto, the
Company will not file with the Commission any other registration statement with respect to its Common Stock, whether for its own account or that of other stockholders, from the date of receipt of a notice from requesting holders pursuant to this
Section 4.1 until the completion of the period of distribution of the registration contemplated thereby or one hundred twenty (120) days after the effective date of such registration, whichever is later. 
 4.2 Incidental Registration. If the Company at any time (other than pursuant to Section 4.1 or Section 4.3) proposes to
register any of its securities under the Securities Act for sale to the public, whether for its own account or for the account of other security holders or both (except with respect to an initial public offering of the Company’s securities
(other than pursuant to Section 4.1) or registration statements on Forms S-4, S-8 or any successor to such forms or another form not available for registering the Registrable Securities for sale to the public), each such time it will
promptly give written notice to all holders of the Registrable Securities of its intention so to do. Upon the written request of any such holder, received by the Company within thirty (30) days after the giving of any such notice by the
Company, to register any or all of its Registrable Securities, the Company will use its best efforts to cause the Registrable Securities as to which registration shall have been so requested to be included in the securities to be covered by the
registration statement proposed to be filed by the Company, all to the extent requisite to permit the sale or other disposition by the holder (in accordance with its written request) of such Registrable Securities so registered. If the registration
of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the holders of Registrable Securities as a part of the written notice given pursuant to this Section 4.2. In
such event the right of any holder of Registrable Securities to registration pursuant to this Section 4.2 shall be conditioned upon such holder’s participation in such underwriting to the extent provided herein. All holders of
Registrable Securities proposing to distribute their securities through such underwriting shall (together with the Company) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for underwriting by the
Company. Notwithstanding any other provision of this Section 4.2, if the underwriter determines that marketing factors require a limitation on the number of shares to be underwritten, the Company shall so advise all holders of securities
requesting registration of any limitations on the number of shares to be underwritten, and the number of shares of securities that are entitled to be included in the registration and underwriting shall be allocated (i) first to 

  

 8 

 
the Company with respect to shares of Common Stock being sold for its own account; and (ii) second, to holders of Registrable Securities requesting
registration in proportion, as nearly as practicable, to the respective amounts of securities owned by them, provided that, notwithstanding the foregoing, at least thirty percent (30%) of the shares to be included in such registration shall be
Registrable Securities. Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section 4.2 without thereby incurring any liability to the holders of Registrable Securities. If
any holder of Registrable Securities disapproves of the terms of any such underwriting, it may elect to withdraw therefrom by written notice to the Company and the underwriter. Any Registrable Securities or other securities excluded or withdrawn
from such underwriting shall be withdrawn from such registration. 
 4.3 Registration on Form S-3. In addition to the rights provided
in Sections 4.1 and 4.2, if at any time (i) the holder or holders of Registrable Securities then outstanding request that the Company file a registration statement on Form S-3 or any comparable or successor form thereto for a
public offering of all or any portion of the shares of Registrable Securities held by such requesting holder or holders, the reasonably anticipated aggregate offering price to the public of which would exceed $2,500,000, and (ii) the Company is
a registrant entitled to use Form S-3 or any comparable or successor form thereto to register such shares, then the Company shall use its best efforts to register under the Securities Act on Form S-3 or any comparable or successor form thereto, for
public sale in accordance with the method of disposition specified in such notice, the number of shares of Registrable Securities specified in such notice. Whenever the Company is required by this Section 4.3 to use its best efforts to
effect the registration of Registrable Securities, each of the procedures and requirements of Sections 4.1 and 4.4, including, but not limited to, the requirement that the Company notify all holders of Registrable Securities from whom
notice has not been received and provide them with the opportunity to participate in the offering, shall apply to such registration, provided, however, that there shall be no limitation on the number of registrations on Form S-3 which
may be requested and obtained under this Section 4.3 except that the Company shall not be required to effect more than one (1) registration pursuant to this Section 4.3 in any twelve (12) month period. 

4.4 Registration Procedures. If and whenever the Company is required by the provisions of Section 4.1, 4.2 or 4.3 to
use its best efforts to effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 
 (a) prepare and file with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to Section 4.1, shall be on Form S-1 or other form of general
applicability satisfactory to the managing underwriter selected as therein provided) with respect to such securities including executing an undertaking to file post-effective amendments and use its best efforts to cause such registration statement
to become and remain effective for the period of the distribution contemplated thereby; provided, that before filing a registration statement or prospectus, the Company shall furnish to the counsel selected by the holders of a majority of the
Registrable Securities covered by such registration statement copies of all such documents proposed to be filed, which documents shall be subject to reasonable review and comment of such counsel; 
  

 9 

 (b) prepare and file with the Commission such amendments and supplements to such registration statement
and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified herein and comply with the provisions of the Securities Act with respect to the disposition of all Registrable
Securities covered by such registration statement in accordance with the sellers’ intended method of disposition set forth in such registration statement for such period and to correct any statements or omissions if, at the time when a
prospectus relating to such securities is required to be delivered under the Securities Act, any event shall have occurred as the result of which any such prospectus or any other prospectus as then in effect would include an untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances in which they were made, not misleading; provided, that before filing any such amendment or supplement, the Company shall
furnish to the counsel selected by the holders of a majority of the Registrable Securities covered by such amendment or supplement copies of all such documents proposed to be filed, which documents shall be subject to the reasonable review and
comment of such counsel; 
 (c) prepare and file with the Commission, promptly upon the request of sellers of Registrable Securities, any
amendments or supplements to such registration statement or prospectus which, in the opinion of counsel for such sellers of Registrable Securities, is required under the Securities Act in connection with the distribution of the Registrable
Securities by such sellers of Registrable Securities; provided, however, that the Company shall only be required to file any such amendment or supplement, if counsel for the Company concurs with counsel for the sellers that there is a need for such
filing to comply with the Securities Act; 
 (d) not file any amendment or supplement to such registration statement or prospectus to which
a majority in interest of such participating sellers of Registrable Securities shall have reasonably objected on the grounds that such amendment or supplement does not comply in all material respects with the requirements of the Securities Act, in
the opinion of counsel to such sellers of Registrable Securities, after having been furnished with a copy thereof in accordance with Section 4.4(b) above, unless in the opinion of counsel for the Company the filing of such amendment or
supplement is reasonably necessary to comply with applicable federal or state law; 
 (e) furnish to each seller of Registrable Securities
and to each underwriter such number of copies of the registration statement and each such amendment and supplement thereto (in each case including all exhibits) and the prospectus included therein (including each preliminary prospectus) as such
persons reasonably may request in order to facilitate the public sale or other disposition of the Registrable Securities covered by such registration statement; 
 (f) use its best efforts to register or qualify the Registrable Securities covered by such registration statement under the securities or “blue sky” laws of such jurisdictions as the sellers of Registrable
Securities or, in the case of an underwritten public offering, the managing underwriter reasonably shall request, provided, however, that the Company shall not for any such purpose be required to qualify generally to transact business
as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general 

  

 10 

 
service of process in any such jurisdiction, unless the Company is already subject to service in such jurisdiction; 
 (g) use its best efforts to list the Registrable Securities covered by such registration statement with any securities exchange on which the Common
Stock of the Company is then listed and, if not so listed, to be listed on the NASD automated quotation system and, if listed on the NASD automated quotation system, use its best efforts to secure designation of all such Registrable Securities
covered by such registration statements as a NASDAQ “national market system security” within the meaning of Rule 11Aa2-1 of the Exchange Act or, failing that, to secure NASDAQ authorization for such Registrable Securities; 
 (h) comply with all applicable rules and regulations under the Securities Act and Exchange Act; 
 (i) provide a transfer agent and registrar for all such Registrable Securities and a CUSIP number for all such Registrable Securities in each case not
later than the effective date of such registration statement. 
 (j) promptly notify each seller of Registrable Securities and each
underwriter under such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus
contained in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the
circumstances then existing, and promptly prepare and furnish to such seller a reasonable number of copies of a prospectus supplemented or amended so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus
shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 
 (k) if the offering is underwritten and at the request of any seller of Registrable Securities, use its best efforts to furnish on the date that
Registrable Securities are delivered to the underwriters for sale pursuant to such registration: (i) an opinion dated such date of counsel representing the Company for the purposes of such registration, addressed to the underwriters to such
effects as reasonably may be requested by counsel for the underwriters, and (ii) a letter dated such date from the independent public accountants retained by the Company, addressed to the underwriters stating that they are independent public
accountants within the meaning of the Securities Act and that, in the opinion of such accountants, the financial statements of the Company included in the registration statement or the prospectus, or any amendment or supplement thereof, comply as to
form in all material respects with the applicable accounting requirements of the Securities Act, and such letter shall additionally cover such other financial matters (including information as to the period ending no more than five (5) business
days prior to the date of such letter) with respect to such registration as such underwriters reasonably may request; 
  

 11 

 (l) make available for inspection by each seller of Registrable Securities, any underwriter
participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such seller or underwriter, reasonable access to all financial and other records, pertinent corporate documents and
properties of the Company, as such parties may reasonably request, and cause the Company’s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in
connection with such registration statement; 
 (m) cooperate with the selling holders of Registrable Securities and the managing
underwriter, if any, to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold, such certificates to be in such denominations and registered in such names as such holders or the managing
underwriter may request at least two (2) business days prior to any sale of Registrable Securities; 
 (n) permit any holder of
Registrable Securities which holder, in the sole and exclusive judgment, exercised in good faith, of such holder, might be deemed to be a controlling person of the Company, to participate in good faith in the preparation of such registration or
comparable statement and to require the insertion therein of material, furnished to the Company in writing, which in the reasonable judgment of such holder and its counsel should be included; 
 (o) in the event of the issuance of any stop order suspending the effectiveness of a registration statement, or of any order suspending or preventing
the use of any related prospectus or suspending the qualification of any common stock included in such registration statement for sale in any jurisdiction, the Company shall use its best efforts promptly to obtain the withdrawal of such order;

 (p) use its best efforts to cause such Registrable Securities covered by such registration statement to be registered with or approved by
such other governmental agencies or authorities as may be necessary to enable the sellers thereof to consummate the disposition of such Registrable Securities; 
 (q) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering and take all
such other actions as the underwriters reasonably request in order to expedite or facilitate the disposition of Registrable Securities; and 
 (r) if at the time of a request for registration pursuant to Section 4.1 or Section 4.3, the Board reasonably determines (upon advice of counsel) that registration of the Registrable Securities would interfere with
any material, non-public transaction involving the Company, the Company may defer the filing of the registration statement for a period of up to 90 days after receipt of the request of the holder or holders pursuant to Section 4.1 and
Section 4.3; provided, that the Company may not exercise this right more once in any twelve (12) month period; provided, further, that the Company shall provide prior notice of such determination
to the requesting holder or holders. 
  

 12 

 For purposes of this Investor Rights Agreement, the period of distribution of Registrable Securities in a
firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of Registrable Securities in any other registration shall
be deemed to extend until the earlier of the sale of all Registrable Securities covered thereby or one hundred eighty (180) days after the effective date thereof, provided, however, in the case of any registration of Registrable
Securities on Form S-3 or a comparable or successor form which are intended to be offered on a continuous or delayed basis, such one hundred eighty (180) day period shall be extended, if necessary, to keep the registration statement effective
until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act
governing the obligation to file a post-effective amendment, permit, in lieu of filing a post-effective amendment which (y) includes any prospectus required by Section 10(a)(3) of the Securities Act or (z) reflects facts or
events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (y) and (z) above contained in periodic reports filed
pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement. 
 In connection with each registration
hereunder, the sellers of Registrable Securities will furnish to the Company, in writing, such information requested by the Company with respect to themselves and the proposed distribution by them as shall be reasonably necessary in order to assure
compliance with Federal and applicable state securities laws. 
 4.5 Expenses. 
 (a) All expenses other than Selling Expenses incurred by the Company in complying with Sections 4.1, 4.2 and 4.3, are called
“Registration Expenses” and shall include, without limitation, (i) all registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses
(including counsel fees) incurred in connection with complying with state securities or “blue sky” laws, fees of the National Association of Securities Dealers, Inc., transfer taxes, fees of transfer agents and registrars, costs of any
insurance which might be obtained by the Company with respect to the offering by the Company, and (ii) reasonable attorneys’ fees and disbursements of one counsel for the holders of Registrable Securities in an amount not to exceed an
aggregate of $35,000, such counsel to be selected by the holders of at least a majority of the Registrable Securities being sold. All underwriting discounts, selling commissions and other expenses not referred to above applicable to the sale of
Registrable Securities are called “Selling Expenses.” 
 (b) The Company shall pay all Registration Expenses in connection
with each registration statement under Section 4.1, 4.2 and 4.3; provided that, in the event of a registration pursuant to Section 4.1 hereof which is withdrawn at the request of the Investors other than
(i) as a result of the Company’s failure to perform its obligations hereunder, (ii) as a result of a cutback by the underwriter of such registration in the amount of Registrable Securities which may be included in such registration by
more than thirty percent (30%), (iii) as a result of information concerning a materially adverse change in the Company’s business or financial condition that is made known to the Investors after the date on which such registration 

  

 13 

 
was requested, (iv) as a result of any general banking moratorium, or (v) as a result of (A) any outbreak or escalation of national or
international hostilities or any crisis or calamity, (B) any change in U.S. or international financial markets, or (C) any substantial change in U.S. or international political, financial or economic conditions, in each case, which is
material and adverse and makes it impracticable to market such Registrable Securities, the Investors shall pay the Registration Expenses with respect to such registration, in which case, the Investors will be deemed not to have used their one demand
registration right under Section 4.1. All Selling Expenses in connection with each registration statement under Section 4.1, 4.2 or 4.3 shall be borne by the participating sellers in proportion to the number of
shares registered by each, or by such participating sellers other than the Company (except to the extent the Company shall be a seller) as they may agree. 
 4.6 Indemnification and Contribution. 
 (a) In the event of a registration of any of the Registrable
Securities under the Securities Act pursuant to Section 4.1, 4.2 or 4.3, the Company (i) will indemnify and hold harmless each holder of Registrable Securities, its officers, directors and partners, each underwriter of
such Registrable Securities thereunder and each other person, if any, who controls such holder or underwriter within the meaning of the Securities Act (each, an “Indemnitee”), against any losses, claims, damages or liabilities,
joint or several, to which such Indemnitee may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (a) any untrue statement
or alleged untrue statement of any material fact contained in any prospectus, offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable Securities were
registered under the Securities Act pursuant to Section 4.1, 4.2 or 4.3, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), (b) any blue sky application or other
document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws
thereof (any such application, document or information herein called a “Blue Sky Application”), (c) any omission or alleged omission to state in any such registration statement, prospectus, amendment or supplement or in any
Blue Sky Applications executed or filed by the Company, a material fact required to be stated therein or necessary to make the statements therein not misleading, (d) any violation by the Company or its agents of the Securities Act or any rule
or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration, or (e) any failure to register or qualify the
Registrable Securities in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company (the undertaking of any underwriter chosen by the Company being attributed to the Company) will undertake such
registration or qualification and (ii) will reimburse each Indemnitee for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after
being so incurred, provided, however, that the Company will not be liable to an Indemnitee if, and to the extent that, any such loss, claim, damage or liability (A) arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission so made in conformity with written information furnished by such Indemnitee, in writing specifically stated to be for 

  

 14 

 
use in such registration statement or prospectus or (B) in a case where a copy of a prospectus (as amended or supplemented) is required to be delivered
by such Indemnitee, and not by any underwriter, is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in a preliminary prospectus and a copy of the prospectus (as amended or supplemented) was not sent or
given by or on behalf of such Indemnitee to the person asserting any such loss, claim, liability or damage (if required by law so to have been delivered) at or prior to the written confirmation of the sale of the Registrable Securities as required
by the Securities Act and the prospectus (as so amended or supplemented) would have corrected such untrue statement or omission or alleged untrue statement or omission; provided that in clause (B), the Company had promptly notified Indemnitee of
such untrue statement or alleged untrue statement or omission or alleged omission in compliance with Section 4.4(h) herein. 
 (b) In the event of a registration of any of the Registrable Securities under the Securities Act pursuant to Section 4.1, 4.2 or 4.3, each seller of such Registrable Securities thereunder, severally and not
jointly, (i) will indemnify and hold harmless the Company, each person, if any, who controls the Company within the meaning of the Securities Act, each officer of the Company who signs the registration statement, each director of the Company,
each other seller of Registrable Securities, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or such
officer, director, other seller, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any
untrue statement or alleged untrue statement of any material fact contained in any prospectus offering circular or other document incident to such registration (including any related notification, registration statement under which such Registrable
Securities were registered under the Securities Act pursuant to Section 4.1, 4.2 or 4.3, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof), or any Blue Sky Application
or arise out of, or are based upon, the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and (ii) will reimburse the Company and each such
officer, director, other seller, underwriter and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action, promptly after being so
incurred, provided, however, that such seller will be liable hereunder in any such case if and only to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in writing to the Company by such seller specifically for use in such registration statement or
prospectus; and provided further, however, that the liability of each seller hereunder shall be limited to the proportion of any such loss, claim, damage, liability or expense which is equal to the proportion that the public offering
price of the securities sold by such seller under such registration statement bears to the total public offering price of all securities sold thereunder, but not in any event to exceed the proceeds received by such seller from the sale of
Registrable Securities covered by such registration statement. Not in limitation of the foregoing, it is understood and agreed that the indemnification obligations of any seller hereunder pursuant to 

  

 15 

 
any underwriting agreement entered into in connection herewith shall be limited to the obligations contained in this Section 4.6(b). 

(c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in
respect thereof is to be made against the indemnifying party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such
indemnified party other than under this Section 4.6 and shall only relieve it from any liability which it may have to such indemnified party under this Section 4.6 if, and to the extent, the indemnifying party is prejudiced
by such omission. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall
wish, to assume and undertake the defense thereof with counsel satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the
indemnifying party shall not be liable to such indemnified party under this Section 4.6 for any legal expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of
investigation and of liaison with counsel so selected, provided, however, that, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably
concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or that the interests of the indemnified party reasonably may be deemed to conflict with the
interests of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate
counsel and other expenses related to such participation to be reimbursed by the indemnifying party as incurred. No indemnifying party, in the defense of any such claim or action, shall, except with the consent of each indemnified party, consent to
entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or action. Each
indemnified party shall furnish such information regarding itself or the claim in question as an indemnifying party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation
resulting therefrom. 
 (d) In order to provide for just and equitable contribution to joint liability under the Securities Act in any case
in which either (i) any holder of Registrable Securities exercising rights under this Investor Rights Agreement, or any controlling person of any such holder, makes a claim for indemnification pursuant to this Section 4.6 but it is
judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 4.6 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any such selling holder or any such controlling person in
circumstances for which indemnification is provided under this Section 4.6; then, and in each such case, the Company and such holder will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject
(after contribution from others) in such 

  

 16 

 
proportion so that such holder is responsible for the portion represented by the percentage that the public offering price of its Registrable Securities
offered by the registration statement bears to the public offering price of all securities offered by such registration statement, and the Company is responsible for the remaining portion, provided, however, that, in any such case,
(A) no such holder of Registrable Securities will be required to contribute any amount in excess of the proceeds received from the sale of all such Registrable Securities offered by it pursuant to such registration statement; and (B) no
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person or entity who was not guilty of such fraudulent misrepresentation. 
 (e) The indemnities and obligations provided in this Section 4.6 shall survive the transfer of any Registrable Securities by such holder.

 4.7 Changes in Common Stock. If, and as often as, there is any change in the Common Stock by way of a stock split, stock dividend,
combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the rights and privileges granted hereby shall
continue with respect to the Common Stock as so changed. 
 4.8 Rule 144 and 144A Reporting. With a view to making available the
benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Registrable Securities to the public without registration, except as provided in paragraph (c) below, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, the Company agrees to: 
 (a) use its best efforts to comply with all of the reporting requirements of the Securities Act and the Exchange Act (whether or not it shall be required to do so) and shall comply with all other public information reporting requirements of
the Commission as a condition to the availability of an exemption from the Securities Act for the sale of any of the Registrable Securities by any holder of Registrable Securities (including any such exemption pursuant to Rule 144 or Rule 144A
thereof, as amended form time to time, or any successor rule thereto or otherwise); 
 (b) cooperate with each holder of Registrable
Securities in supplying such information as may be necessary for such holder of Registrable Securities to complete and file any information reporting forms presently or hereafter required by the Commission as a condition to the availability of an
exemption from the Securities Act (under Rule 144 or Rule 144A thereunder or otherwise) for the sale of any of the Registrable Securities by any holder of Registrable Securities; and 
 (c) furnish to each holder of Registrable Securities forthwith upon request a written statement by the Company as to its compliance with the reporting
requirements of such Rule 144 or Rule 144A (or any successor rule) and, at any time after it has become subject to such reporting requirements, of the Securities Act and the Exchange Act, a copy of the most recent annual or quarterly report of the
Company, and such other reports 

  

 17 

 
and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such
holder to sell any Registrable Securities without registration. 
 4.9 “Market Stand-Off” Agreement. Each of the Investors
agrees, severally and not jointly, that, if requested by the Company and an underwriter of Common Stock (or other securities) of the Company, not to sell or otherwise transfer or dispose of any Common Stock (or other securities) of the Company held
by such Investor during a period not to exceed one hundred and eighty (180) days (which period may be extended upon the request of the managing underwriter, in order to permit its compliance with applicable NASD rules in the event the Company
issues or proposes to issue an earnings or other public release within seventeen (17) days of the expiration of the 180-day lockup period) (the “Market Stand-Off Period”) following the effective date of the first registration
statement of the Company filed under the Securities Act and to enter into an agreement to such effect regardless of whether such Investor is participating in the offering to which the registration statement relates, provided that all directors,
officers, and holders of greater than one percent (1%) of the Common Stock (calculated on an as-converted basis, and assuming the exercise of all rights, options and warrants and conversion of all convertible securities) agree to enter into
similar agreements containing terms no more favorable to such other holders of Common Stock. Notwithstanding the foregoing, the Market Stand-Off Period shall be extended beyond the 180-day period referenced above for an additional one hundred and
eighty-five (185) days (which period may be extended upon the request of the managing underwriter, in order to permit its compliance with applicable NASD rules in the event the Company issues or proposes to issue an earnings or other public
release within seventeen (17) days of the expiration of the 180-day lockup period) in the event that the Company consummates a Qualified Public Offering on or before June 30, 2008, provided that all directors, officers, and holders of
greater than one percent (1%) of the Common Stock (calculated on an as-converted basis, and assuming the exercise of all rights, options and warrants and conversion of all convertible securities) are subject to the same extension. 

The Company may impose stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of
said period. 
 4.10 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to
this Section 4 may only be assigned to (a) an Affiliate of an Investor or another Investor, or (b) any other transferee who acquires at least thirty-five percent (35%) of such transferring Investor’s shares of
Preferred Stock, and in each case, only if such Affiliate or transferee agrees in writing to be bound to the terms, agreements and restrictions contained in this Investor Rights Agreement. In no event shall such rights be assigned to a competitor of
the Company as determined by the Board in its sole discretion. 
 4.11 Grant of Subsequent Registration Rights. Subsequent to the
execution of this Agreement, the Company shall not grant registration rights to any holder of Common Stock (calculated on an as-converted basis, and assuming the exercise of all rights, options and warrants and conversion of all convertible
securities) of the Company unless such registration rights are subordinate to the registration rights of the Investors. 
  

 18 

 4.12 Termination. The respective rights and
obligations of the parties under this Section 4 shall terminate upon the earlier of (i) the fifth (5th) anniversary of the closing of
the Company’s Qualified Public Offering and (ii) with respect to any holder of not more than one hundred thousand (100,000) Registrable Securities, when such holder can sell all of such holder’s shares under Rule 144 promulgated
under the Securities Act without regard to time or volume limitations. 
 5. AFFIRMATIVE COVENANTS OF THE COMPANY 

The Company covenants and agrees that, from the date of the Closing under the Purchase Agreement and thereafter so long as any Investor owns at least
twenty-five percent (25%) of the outstanding shares of Preferred Stock initially purchased by such Investor pursuant to the Purchase Agreement (each, a “Rights Holder”), it will perform and observe the following covenants and
provisions. 
 5.1 Corporate Existence. The Company will maintain and will cause any Subsidiary or future Subsidiary to maintain its
corporate existence in good standing and comply with all applicable laws and regulations of the United States, of any state or states thereof, any political subdivision thereof and of any governmental authority. In the event that the Company
hereafter acquires one or more Subsidiaries, the covenants of the Company set forth in this Section 5 will apply where relevant to such Subsidiary(ies) as well as to the Company. 
 5.2 Compliance with Laws. The Company shall comply with all applicable laws, rules, regulations and orders, noncompliance with which could
materially adversely affect its respective business or condition, financial or otherwise 
 5.3 Financial Statements; Other Reports.
The Company shall maintain proper books of account and records in accordance with generally accepted accounting principles applied on a consistent basis, and shall deliver: 
 (a) to each Rights Holder who so requests, as soon as available and in any event within thirty (30) days after the end of each month, an unaudited
consolidated balance sheet of the Company and its Subsidiaries, if any, as of the end of such month and the related unaudited statements of income and stockholders’ equity and of cash flows of the Company for the period commencing at the end of
the previous fiscal year and ending with the end of such month, setting forth in each case in comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in
reasonable detail and prepared in accordance with generally accepted accounting principles consistently applied, and duly certified (subject to year-end audit adjustments) by the chief financial officer of the Company; 
 (b) to each Rights Holder, as soon as available and in any event within forty-five (45) days after the end of each of the first three quarters of
each fiscal year of the Company, an unaudited consolidated balance sheet of the Company and its Subsidiaries, if any, as of the end of such quarter and the related unaudited statements of income and stockholders’ equity and of cash flows of the
Company for the period commencing at the end of the previous fiscal year and ending with the end of such quarter, setting forth in each case in 

  

 19 

 
comparative form the corresponding figures for the corresponding period of the preceding fiscal year and the budget for such current year, all in reasonable
detail and prepared in accordance with generally accepted accounting principles consistently applied, and duly certified (subject to year-end audit adjustments) by the chief financial officer of the Company; 
 (c) to each Rights Holder, as soon as available and in any event within ninety (90) days after the end of each fiscal year of the Company, a copy
of the audited financial statements for such year for the Company, prepared in accordance with generally accepted accounting principles, including therein a consolidated balance sheet of the Company and its Subsidiaries, if any, as of the end of
such fiscal year and statements of income and stockholders’ equity and of cash flows of the Company for such fiscal year, setting forth in each case in comparative form the corresponding figures for the preceding fiscal year, all duly certified
by independent public accountants selected and approved by the Board or the Audit Committee; 
 (d) to each Rights Holder, promptly upon
receipt thereof, any written report submitted to the Company by independent public accountants in connection with an annual or interim audit of the books of the Company made by such accountants; 
 (e) to each Rights Holder, promptly after receipt thereof, notice of all material actions, suits and proceedings before any court or governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, affecting the Company or any litigation-related letters, notices and filings; 
 (f) to each Rights Holder, at least forty-five (45) days prior to the beginning of each fiscal year of the Company, an annual operating plan with monthly and quarterly breakdowns (the “Budget”)
for each fiscal year, as soon as it is made available to the Board; and 
 (g) to each Rights Holder, within seven (7) working days
after coming to the attention of the Company or one of its officers, notice of bona fide investment opportunities from outside investors as well as bona fide merger or sale opportunities. 
 Neither the foregoing provisions of this Section nor any other provision of this Investor Rights Agreement shall be in limitation of any rights which an
Investor may have with respect to the books and records of the Company, or to inspect their properties or discuss their affairs, finances and accounts, under the laws of the jurisdictions in which they are incorporated. 
 5.4 Inspection and Other Information. Each Investor and such agents, advisors and counsel as such Investor may designate, may, at its expense,
visit and inspect any of the properties of the Company, examine the books of account of the Company, take extracts therefrom and discuss the affairs, finances and accounts of the Company with its officers and employees and public accountants (and by
this provision the Company hereby authorizes said accountants to discuss with such Investors its finances and accounts), at reasonable times and with reasonable prior notice during normal business hours, and shall have the right to organize monthly
calls with management of the Company. All such visits and inspections shall be conducted in a manner which will not unreasonably interfere with the normal business operations 

  

 20 

 
of the Company. The Company shall furnish to each such Investor such other information as it from time to time may reasonably request. 
 5.5 Meetings and Committees of the Board of Directors. 
 (a) The Company agrees that it shall cause meetings of the Board to be called not less often than once every two months until such time as the Board determines that bi-monthly meetings are no longer required, and
thereafter not less often than once each calendar quarter. The Company shall give notice of each such meeting to the Series A/B Directors (as defined in the Amended and Restated Certificate of Incorporation) and shall provide copies of minutes of
all actions taken by the Board of Directors, whether at meetings or by written consent, to the Investors. 
 (b) The Board shall establish
such committees as may be necessary and appropriate for conduct of its affairs, which shall include at least a Compensation Committee and an Audit Committee. 
 (i) The Compensation Committee shall be responsible for making recommendations on management compensation, the adoption of employee benefit plans, stock option or equity incentive plans and other similar matters. The
Compensation Committee shall consist of one or more of the Series A/B Directors, one independent director, and the Chief Executive Officer in an ex-officio, non-voting capacity. Decisions of the Compensation Committee shall be determined by a
majority vote of the committee. 
 (ii) The Audit Committee shall consist of at least two directors, which shall not include the Chief
Executive Officer of the Company or any director currently employed or retained by the Company. The Audit Committee shall be responsible for recommending an independent public accounting firm to act as auditors for the Company, meeting with the
auditors to establish the terms of their engagement and scope of the audit, and meeting with the auditors to review the results of the audit and any management letter the auditors determine necessary. The Audit Committee shall also evaluate the
adequacy of the Company’s internal accounting controls and personnel and performing such other function as are appropriate for an audit committee. 
 (iii) The Company will reimburse directors and any authorized board observers for reasonable and necessary direct out-of-pocket expenses (including travel expenses) related to attendance at Board meetings and
committees of the Board in accordance with the Company’s policies and procedures in effect from time to time. 
 5.6 Directors’
and Officers’ Liability Insurance; Key-Man Life Insurance. The Company shall maintain a directors’ and officers’ liability insurance policy on the directors and officers of the Company with a financially sound and reputable
insurance company or association in the amount of at least $3,000,000 in the aggregate. The Company has a key-man life insurance policy on the life of Gerald Wisler in the amount of $2,000,000; however, promptly following the Closing, the Company
shall increase the amount of such policy to $3,000,000. 
  

 21 

 5.7 Confidentiality, Non-Competition and Invention Assignment Agreements. The Company shall obtain
Confidentiality, Non-Competition and Invention Assignment Agreements, in the substantially the form attached as Exhibit B to the Purchase Agreement, from all employees of and consultants to the Company whether now or hereafter employed or
engaged. 
 5.8 Use of Proceeds. The Company shall use the proceeds from the sale of the Shares (the “Proceeds”) for
general corporate and working capital purposes. 
 5.9 Adverse Change. The Company will promptly advise the Investors of any event
which represents a material adverse change in the condition or business, financial or otherwise, of the Company or any subsidiary. 
 5.10
Stock Plan. With respect to all equity issuances granted under any stock plan the Company may now have in effect or may hereafter adopt, the Company agrees that, unless a majority of the Series A/B Directors has consented otherwise:

 (a) The equity issuances shall vest according to the following 4 year schedule: twenty-five percent (25%) of such equity issuance
grant shall vest upon the first yearly anniversary of the grant date, and the remaining unvested portion of such equity issuance shall vest in equal quarterly installments thereafter; 
 (b) The grant of the equity issuances shall be made at the sole and complete discretion of the Board or the Compensation Committee; 
 (c) The equity issuances may not contain acceleration provisions; 
 (d) The holders of securities issued pursuant to any such stock plan that, as a result of such issuance, would own one percent (1%) or more of the Common Stock then outstanding (calculated on an as-converted
basis, and assuming the exercise of all rights, options and warrants and conversion of all convertible securities) shall be subject to (i) the Rights of First Refusal in respect of such securities as set forth in Section 1 of the
Amended and Restated Stockholders’ Agreement of even date herewith entered into by the Company, the Investors and certain other stockholders (the “Stockholders’ Agreement”), or (ii) a similar contractual right of
first refusal in favor of the Company; and 
 (e) The holders of securities issued pursuant to any such stock plan that, as a result of such
issuance or sale, would own one percent (1%) or more of the Common Stock then outstanding (calculated on an as-converted basis, and assuming the exercise of all rights, options and warrants and conversion of all convertible securities) shall be
subject to (i) the Drag Along Rights in respect of such securities as set forth in Section 3 of the Stockholders’ Agreement, or (ii) a similar contractual Drag Along Right in favor of the Company. 
 5.11 Termination of Affirmative Covenants. The covenants set forth in this Section 5 shall be of no further force or effect upon the
closing of the Company’s Qualified Public Offering. 
  

 22 

 6. MISCELLANEOUS 
 6.1 Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be addressed to the receiving party’s address set forth below or to such other address as a party
may designate by notice hereunder, and shall be delivered (i) by hand, (ii) by telecopy or facsimile transmission, (iii) by a nationally recognized (or substantially equivalent international) overnight courier, or (iv) by
registered or certified mail, return receipt requested, postage prepaid. 
  

			
	If to the Company:	  	Aegerion Pharmaceuticals, Inc.
		  	CenterPointe IV
		  	1140 Route 22 East, Suite 304
		  	Bridgewater, NJ 08807
		  	Attn: Gerald Wisler,
		  	President and Chief Executive Officer
		  	(908) 704-1300 (Telephone)
		  	(908) 541-1155 (Fax)
		  	
		  	
	With a copy to:	  	Goodwin Procter LLP
		  	53 State Street
		  	Boston, MA 02109
		  	Attn: Michael H. Bison, Esq.
		  	(617) 570-1933 (Telephone)
		  	(617) 523-1231 (Fax)
		  	
		  	
	If to the Investors:	  	To the addresses set forth on Schedule I.
		  	
		  	
	With a copy to:	  	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		  	One Financial Center
		  	Boston, MA 02111
		  	Attn: Lewis Geffen, Esq.
		  	(617) 348-1834 (Telephone)
		  	(617) 542-2241 (Fax)

 All notices, requests, consents and other communications hereunder shall be deemed to have been
given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if made by telecopy or facsimile transmission, at the time that receipt thereof has been
acknowledged by electronic confirmation or otherwise, (iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the
fifth business day following the day such mailing is made. 
 6.2 Additional Investors. Notwithstanding anything to the contrary
contained herein, if the Company issues additional shares of the Company’s Preferred Stock after the date 

  

 23 

 
hereof, any purchaser of such shares of Preferred Stock shall (a) become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement and thereafter shall be deemed an Investor for all purposes hereunder and (b) become a party to a stock purchase agreement with respect to the purchase of such shares of Preferred Stock that is substantially
similar to the Purchase Agreement. 
 6.3 Entire Agreement. This Investor Rights Agreement embodies the entire agreement and
understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or
agreement of any kind not expressly set forth in this Investor Rights Agreement shall affect, or be used to interpret, change or restrict, the express terms and provisions of this Investor Rights Agreement. 
 6.4 Modifications and Amendments. This Investor Rights Agreement may not be amended or modified, and no provision hereof may be waived, without
the written consent of the Company and the Required Series A/B Majority. Any waiver or consent hereunder shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or
consent. 
 6.5 Benefit. All statements, representations, warranties, covenants and Investor Rights Agreements in this Investor Rights
Agreement shall be binding on the parties hereto and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. 
 6.6 Governing Law. This Investor Rights Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the General Corporation Law of the State of
Delaware as to matters within the scope thereof, and as to all other matters shall be construed in accordance with and governed by the internal laws of the State of New Jersey, without giving effect to the conflict of law principles thereof.

 6.7 Jurisdiction and Service of Process. Any legal action or proceeding with respect to this Agreement may be brought in the
federal courts of the United States of America for the Southern District of New York. By execution and delivery of this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the
jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably consents to the service of process of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid,
to the party at its address set forth in Section 6.1 hereof. 
 6.8 Jury Waiver. Each of the parties hereto irrevocably
waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this agreement or any other document. 
 6.9 Severability. In the event that it is determined that any provision, or any portion thereof, contained in this Investor Rights Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the
extent that it shall be deemed enforceable and as so limited, shall remain in full force and effect. In the event that any such 

  

 24 

 
provision, or portion thereof, is deemed wholly unenforceable, the remaining provisions of this Investor Rights Agreement, nevertheless, shall remain in full
force and effect. 
 6.10 Headings and Captions. The headings and captions of the various subdivisions of this Investor Rights
Agreement are for convenience of reference only and shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof. 
 6.11 Enforcement. Each of the parties hereto acknowledges and agrees that the rights acquired by each party hereunder are unique and that irreparable damage would occur in the event that any of the provisions
of this Investor Rights Agreement to be performed by the other parties were not performed in accordance with their specific terms or were otherwise breached. Accordingly, in addition to any other remedy to which the parties hereto are entitled at
law or in equity, each party hereto shall be entitled to an injunction or injunctions to prevent breaches of this Investor Rights Agreement by any other party. 
 6.12 No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under this Investor Rights Agreement, and no course of dealing among the parties
hereto, shall operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Investor Rights Agreement by a party hereto, nor any abandonment or discontinuance of steps to
enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not constitute a waiver
of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Investor Rights Agreement shall entitle the party receiving such notice or demand to any other or further notice or
demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 
 6.13 Counterparts. This Investor Rights Agreement may be executed in two or more counterparts, and by different parties hereto on separate
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Investor Rights Agreement may be executed by facsimile signatures. 
 6.14 Termination of Conflicting Rights. To the extent any of the Investors are party to a restricted stock agreement that contains provisions that
conflict with the provisions herein, the provisions herein shall supersede such original provisions and each such Investor agrees that such original provisions are hereby terminated; provided, however, that all of the other provisions
set forth in the restricted stock agreements shall remain in full force and effect. 
 6.15 Assignment. Subject to
Section 4.10, each Investor may assign its rights hereunder to any purchaser or transferee of the Registrable Securities; provided, however, that such purchaser or transferee shall, as a condition to the effectiveness of such assignment,
be required to execute a counterpart to the Agreement agreeing to be treated as an Investor whereupon such purchaser or transferee shall have the benefits of, and be subject to the restrictions contained in this Agreement as if such purchaser or
transferee was originally included in the definition of an Investor herein and had originally been a party hereto. 
 . 
  

 25 

 IN WITNESS WHEREOF, the parties hereto have executed this Amended and Restated Investor Rights Agreement
or caused this Amended and Restated Investor Rights Agreement to be executed by their duly authorized representatives as of the date first written above. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	/S/  GERALD WISLER
		 	 Gerald Wisler
 Chief Executive Officer and President

 [Counterpart Signature Pages Begin on Next Page] 
 Signature Page to Amended and Restated Investor Rights Agreement 

 Counterpart Signature Page For Investors 
 The undersigned hereby agrees to become a party to that certain Amended and Restated Investor Rights Agreement dated as of November 9, 2007 (the
“Agreement”) by and among Aegerion Pharmaceuticals, Inc. (the “Company”) and others set forth on the signature pages thereto. From and after the undersigned’s execution and delivery and the Company’s
acceptance of this Counterpart Signature Page, the undersigned shall be an “Investor”, as defined in the Agreement. 
 INDEX VENTURES III
(DELAWARE) L.P. 
  

			
	 By:
	 	Index Venture Associates III Limited, its General Partner
		
	 By:
	 	/s/ D.A. Hall
		 	 
	 Name:
	 	D.A. Hall
	 Title:
	 	Director

 INDEX VENTURES III (JERSEY) L.P. 
  

			
	 By:
	 	Index Venture Associates III Limited, its General Partner
		
	 By:
	 	/s/ D.A. Hall
		 	 
	 Name:
	 	D.A. Hall
	 Title:
	 	Director

 INDEX VENTURES III PARALLEL ENTREPRENEUR FUND (JERSEY) L.P. 
  

			
	 By:
	 	Index Venture Associates III Limited, its General Partner
		
	 By:
	 	/s/ D.A. Hall
		 	 
	 Name:
	 	D.A. Hall
	 Title:
	 	Director

 YUCCA PARTNERS LP JERSEY BRANCH 
  

			
	 By:
	 	 Ogier Employee Benefit Services Limited, as Authorized Signatory
 in its capacity as Administrator of the Index Co-Investment Scheme

		
		 	
	 By:
	 	 /s/ Peter Le Breton

	 Name:
	 	Peter Le Breton
	 Title:
	 	Authorized Signatory

 ADVENT HEALTHCARE AND LIFE SCIENCES III-A LIMITED PARTNERSHIP 
  

			
	 By:
	 	AHLS III GP Limited Partnership, its General Partner
	 By:
	 	Advent International LLC, its General Partner
	 By:
	 	Advent International Corporation, its Manager
		
	 By:
	 	/s/ Jason Fisherman
	 Name:
	 	Jason Fisherman
	 Title:
	 	Vice President/Senior Vice President

 Signature Page to Amended and Restated Investor Rights Agreement 

 ADVENT HEALTHCARE AND LIFE SCIENCES III GP LIMITED PARTNERSHIP 
  

			
	 By:
	 	AHLS III GP Limited Partnership, its General Partner
	 By:
	 	Advent International LLC, its General Partner
	 By:
	 	Advent International Corporation, its Manager
		
	 By:
	 	/s/ Jason Fisherman
	 Name:
	 	Jason Fisherman
	 Title:
	 	Vice President/Senior Vice President

 ADVENT PARTNERS HLS III LIMITED PARTNERSHIP 
  

			
	 By:
	 	Advent International Corporation, its General Partner
		
	 By:
	 	/s/ Jason Fisherman
		 	 
	 Name:
	 	Jason Fisherman
	 Title:
	 	Vice President/Senior Vice President

 ALTA BIOPHARMA PARTNERS III, L.P. 
  

			
	 By:
	 	Alta BioPharma Management III, LLC
		
	 By:
	 	/s/ Hilary Strain
		 	 
	 Name:
	 	Hilary Strain
	 Title:
	 	V.P. of Finance & Admin

 ALTA BIOPHARMA PARTNERS III GMBH & CO. BETEILIGUNGS KG 
  

			
	 By:
	 	Alta BioPharma Management III, LLC
		
	 By:
	 	/s/ Hilary Strain
		 	 
	 Name:
	 	Hilary Strain
	 Title:
	 	V.P. of Finance & Admin

 ALTA EMBARCADERO BIOPHARMA PARTNERS III, LLC 
  

			
		
	By:	 	/s/ Hilary Strain
	 Name:
	 	Hilary Strain
	 Title:
	 	V.P. of Finance & Admin

 MC LIFE SCIENCE VENTURE, INC. 
  

			
		
	By:	 	/s/ Tsunehiko Yanagihara
	 Name:
	 	Tsunehiko Yanagihara
	 Title:
	 	President

 Signature Page to Amended and Restated Investor Rights Agreement 

 RED ABBEY VENTURE PARTNERS (QP), LP 
  

			
	 By:
	 	Red Abbey Ventures Partners, LLC, its General Partner
		
	 By:
	 	/s/ Matt Zuga
		 	 
	 Name:
	 	Matt Zuga
	 Title:
	 	Managing Member

 RED ABBEY VENTURE PARTNERS, LP 
  

			
	 By:
	 	Red Abbey Ventures Partners, LLC, its General Partner
		
	 By:
	 	/s/ Matt Zuga
		 	 
	 Name:
	 	Matt Zuga
	 Title:
	 	Managing Member

 RED ABBEY CEO’S FUND, LP 
  

			
	 By:
	 	Red Abbey Ventures Partners, LLC, its General Partner
		
	 By:
	 	/s/ Matt Zuga
		 	 
	 Name:
	 	Matt Zuga
	 Title:
	 	Managing Member

 MVM INTERNATIONAL LIFE SCIENCES FUND NO. 1 LP 
  

			
	 By:
	 	MVM Life Science Partners LLP, its Manager
		
	 By:
	 	/s/ Hugo Harrod
		 	 
	 Name:
	 	Hugo Harrod
	 Title:
	 	Member

 MVM EXECUTIVE LIMITED 
  

			
	 By:
	 	MVM Life Science Partners LLP, its Director
		
	 By:
	 	/s/ Hugo Harrod
		 	 
	 Name:
	 	Hugo Harrod
	 Title:
	 	Member

 SERVENTIA SA 
  

			
		
	By:	 	/s/ F. Ghioldi
	 Name:
	 	F. Ghioldi
	 Title:
	 	Director

 HERCULES TECHNOLOGY GROWTH CAPITAL, INC. 
  

			
		
	By:	 	/s/ K. Nicholas Martitsch
	 Name:
	 	K. Nicholas Martitsch
	 Title:
	 	Associate General Counsel

 Signature Page to Amended and Restated Investor Rights Agreement 

 JAWZ II LLC 
  

			
		
	By:	 	/s/ James M. Wisler
	 Name:
	 	James M. Wisler
	 Title:
	 	Manager
		
	 By:
	 	/s/ Will Lewis
		 	 
		
	 By:
	 	/s/ David Arkowitz
		 	 
		
	 By:
	 	/s/ Eileen More
		 	 

 Signature Page to Amended and Restated Investor Rights Agreement 

 SCHEDULE I 
 INVESTORS 
 Advent Healthcare and Life Sciences III Limited Partnership 
 75 State Street 
 Boston, MA 02109 
 Attn: Health and Life Science Funds Director 
 Advent Healthcare and Life
Sciences III-A Limited Partnership 
 75 State Street 
 Boston, MA
02109 
 Attn: Health and Life Science Funds Director 
 Advent
Partners HLS III Limited Partnership 
 75 State Street 
 Boston,
MA 02109 
 Attn: Health and Life Science Funds Director 
 Alta
BioPharma Partners III, L.P. 
 One Embarcadero Center, Suite 3700 
 San Francisco, CA 94111 
 Alta BioPharma Partners III GmbH & Co. Beteiligungs KG 
 One Embarcadero Center, Suite 3700 
 San Francisco, CA 94111 
 Alta Embarcadero BioPharma Partners III, LLC 
 One Embarcadero Center, Suite
3700 
 San Francisco, CA 94111 
 Yucca Partners LP Jersey Branch

 Whiteley Chambers, Don Street 
 Jersey JE4 9WG 
 Channel Islands 
 Index Ventures III (Delaware) L.P. 
 P.O. Box 641 
 No. 1 Seaton Place 
 St. Helier 
 Jersey JE4 8YJ 
 Channel Islands 
 Facsimile: +441534 605 605 
 Attention: David Hall 
  

 Index Ventures III (Jersey) L.P. 
 P.O. Box 641 
 No. 1 Seaton Place 
 St. Helier

 Jersey JE4 8YJ 
 Channel Islands 
 Facsimile: +441534 605 605 
 Attention: David Hall 
 Index Ventures III Parallel Entrepreneur Fund (Jersey) L.P. 
 P.O. Box 641

 No. 1 Seaton Place 
 St. Helier 
 Jersey JE4 8YJ 
 Channel Islands 
 Facsimile: +441534 605 605 
 Attention: David Hall 
 MVM International Life Sciences Fund No. 1. LP 
 6 Henrietta Street

 London WC2E 8PU 
 MVM Executive Limited 
 6 Henrietta Street 
 London WC2E 8PU 
 MC Life Science Ventures, Inc. 
 c/o Mitsubishi International Corporation

 Life Science Business Dept. 
 655 Third Avenue 
 New York, NY 10017 
 Red Abbey Venture Partners (QP), LP 
 2330 West Joppa Road, Suite 330 
 Lutherville, MD 21093 
 Red Abbey Venture Partners, LP 
 2330 West Joppa Road, Suite 330 

Lutherville, MD 210093 
 Red Abbey CEO’s Fund, LP 
 2330 West Joppa Road, Suite 330 
 Lutherville, MD 210093 
  

 Hercules Technology Growth Capital, Inc. 
 400 Hamilton Avenue, Suite 310 
 Palo Alto, CA 94301 
 David Brister 
 6 Henrietta Street 
 London WC2E 8PU 
 Martin Murphy 
 6 Henrietta Street

 London WC2E 8PU 
 Richard Lim 
 6 Henrietta Street 
 London WC2E 8PU 
 Thomas Casdagli 
 6 Henrietta Street 
 London WC2E 8PU 
 Stephen Reeders 
 6 Henrietta Street 
 London WC2E 8PU 
 Jawz II LLC 
 P.O. Box 630440 
 Highlands Ranch, CO 80124 
 Serventia SA, Lugano 
 William H. Lewis 
 31
West 21 st , Apt. #5 
 New York, New York 10010

 Serventia SA 
 Via Marconi 4 
 Lugano CH-6901 
 Eileen More 
 36 Weston Road 
 Weston, CT 06883 
 William Lewis 
 22 Canterbury Lane 
 Summit, NJ 07901 
  

 David Arkowitz 
 627 Chestnut
Street 
 Waban, MA 02968

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]